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Abstract 
Van der Heijden, M.H.T., 1996. Impact of antibacterial drugs on the health of European eel. 
Ph.D. thesis, Wageningen Institute of Animal Sciences, Wageningen Agricultural University, 
P.O.Box 338, 6700 AH Wageningen, The Netherlands. 
Application of antibacterial drugs plays an important role in the control of bacterial diseases 
in intensive fish culture. However, since the scientific basis for the use of these drugs is yet 
inadequate, there is a growing concern about the safety of fish medication for the consumer, 
the environment and the target animals. This led to the research presented in this thesis, 
which is focused on the influence of the antibacterial drug flumequine on the defence 
system of European eel (Anguilla anguilla L., 1758). Eel appeared to be an interesting 
model because the initial, pharmacokinetic investigations demonstrated that flumequine is 
very slowly eliminated from both plasma and tissues in this species. Treatment of eels with 
flumequine resulted in an enhanced proliferation of (probably surface immunoglobulin 
negative) lymphoid cells as assessed by means of an in vivo lymphocyte stimulation assay 
and monoclonal antibodies to eel immunoglobulin, respectively. The effect of the drug on 
the integral functioning of the defence system was subsequently examined by using a 
challenge with the parasitic nematode Anguillicola crassus. The resulting parasite recoveries 
pointed to an improved protection in flumequine-treated eels, which seemed to be related 
to a modulation of the cellular response. 
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Stellingen 
1. Voor het aantonen van antilichaam responsen tegen Anguillicola crassus bij aal zijn 
frequente infecties met infectieuze larven van deze parasiet noodzakelijk. Dit proefschrift 
2. Het immunostimulerende effect van flumequine mag niet bepalend zijn voor het gebruik 
hiervan in de aalteelt. Dit proefschrift 
3. Ook voor farmacotherapie geldt: de ene vis is de andere niet. Dit proefschrift 
4. De relevantie van in vitro vastgestelde immunotoxiciteit dient gevalideerd te worden 
met behulp van in vivo testen. 
5. Gezien de specifieke complicaties bij de diagnose en behandeling van visziekten is 
ziektepreventie in de visteelt nog belangrijker dan in andere vormen van dierhouderij. 
6. Onderzoek naar de invloed van geneesmiddelen op de afweer leidt tot efficiëntere 
ziektetherapieé'n. 
7. De beperkte toegankelijkheid van de Japanse literatuur werkt vertragend op het 
Europese onderzoek aan aal. 
8. Bij een discussie over het al dan niet opnemen van de evolutietheorie in het 
eindexamen voor middelbare scholieren dient de nadruk te liggen op de bruikbaarheid van 
deze theorie voor de verklaring van biologische verschijnselen. 
9. Door het ontbreken van visziekte-onderwijs in het curriculum van aanstaande 
dierenartsen is het ongeloofwaardig dat het recht tot het voorschrijven van geneesmiddelen 
voor vissen aan dierenartsen is voorbehouden. 
10. Gezien de bezuinigingen op de budgetten in het wetenschappelijk onderwijs is de 
winststijging van de KLM niet veroorzaakt door een toename in het bezoek van 
internationale congressen door Nederlandse universitaire medewerkers. 
11. Bij het uitblijven van adequate maatregelen ten aanzien van de controle op residuen van 
geneesmiddelen in consumptievis zou deze op termijn nog slechts op recept verkrijgbaar 
moeten zijn. 
Stellingen behorend bij het proefschrift "Impact of antibacterial drugs on the health of European eel" 
van M.H.T. van der Heijden. Wageningen, 1 april 1996. 
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Introduction 
The global increase in fish culture production is a result of both aquaculture area 
expansion and production intensification (Huisman et al, 1993; Anonymous, 1994). 
High densities of fish stocks in intensive aquaculture systems are accompanied by an 
increased prevalence of infectious diseases as a result of a higher infection pressure and 
decreased resistance of the fish (Roberts, 1989). Economical losses related to diseases 
are caused by reduced growth and morbidity and mortality among the animals. It is 
attempted to minimize these losses by optimization of culture conditions through 
zootechnical and hygienic measures. Also, vaccination is a promising approach, but, for 
the time being, effective vaccines are only available for a limited range of fish 
pathogens (Ellis, 1988). However, in view of the limitations of the control methods 
mentioned, chemotherapy is still considered the most effective weapon against infectious 
diseases in aquaculture (Gratzek, 1983; Stuart, 1983). In as far as bacterial infections are 
concerned, a variety of antibacterial drugs is used, curatively as well as prophylactically 
(Austin, 1984). 
Although antibacterial drugs are known to be of remarkable value for the control 
of bacterial fish diseases (Gratzek, 1983; Ellis, 1988), a growing interest in the possible 
hazards due to the use of these drugs in aquaculture can be observed. Bernoth (1991) 
paid attention to the risks concerning public health, i.e. residues of drugs in fish destined 
for human consumption, development of resistance in human pathogenic bacteria and 
the direct toxic effects on humans from handling the drugs. Furthermore, treatment of 
fish causes pollution of the environment, which may result in a negative selective 
influence on the growth of the normal bacterial fauna and an increase of resistant 
pathogens (Austin, 1985; Lunestad, 1992; Samuelsen, 1993). Last but not least, 
antibacterial drugs can exhibit undesired side effects on the health of the target animals. 
Among these, gastro-intestinal disturbances, damage to organs such as liver and kidney, 
and superinfections with viruses, resistant bacteria, fungi and parasites have been 
described in clinical reports (Garrod et al, 1973). Prolonged exposure to higher 
concentrations of a drug, as may be expected in liver and kidney, seems to affect the 
occurrence of lesions. Moreover, especially rapidly dividing cells like intestinal 
epithelium and activated lymphocytes appear to be prone to toxic effects of drugs 
(Claassen, 1991). 
During the last decades, studies have been performed on the interaction between 
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antibacterial drugs and the immune system in mammals, birds and fish (Grondel and van 
Muiswinkel, 1986). Some antibacterial drugs have shown to interfere with the 
immunological defence mechanisms. This interference may result in immunostimulation 
or immunosuppression. The latter situation is greatly undesirable, because an optimal 
immune function is important for both the final elimination of the pathogens that gave 
rise to the therapy and the resistance against new infections. Immunostimulation, on the 
other hand, fits within the purpose of an antibacterial treatment, because it may enhance 
defusion and elimination of the pathogen. 
A widespread use of antibacterial drugs in intensive fish culture systems, in 
combination with their potential immunomodulating properties and the associated 
influence on the health of treated animals, gave cause to the research presented in the 
current thesis. This chapter is a general introduction to the basic subjects raised in the 
thesis. First, some aspects of the biology and culture of European eel {Anguilla anguilla 
L., 1758), the central species in the experiments described, will come up. Secondly, 
attention will be paid to the antibacterial drugs and the pharmacokinetics of such drugs 
in fish. Subsequently, the immune system of teleost fish will be briefly discussed, 
followed by some comments on immunomodulation and the assays to detect it. Finally, 
the aim and outline of the thesis will be described. 
European eel (Anguilla anguilla L., 1758) 
Biology of the European eel 
Since ancient times many people look upon eels as mysterious, snake-like creatures 
because of their peculiar habits and unusual body shape. Numerous scientific 
investigations on eel biology (Liewes, 1981; Tesch, 1983; Deelder, 1984; Tesch, 1991) 
have contributed to an increased knowledge and understanding of these fish. 
Nevertheless, important aspects of their live and functioning still have to be elucidated. 
The European eel {Anguilla anguilla L., 1758), which is among the best studied 
eels, is a teleost fish classified in the genus Anguilla (Shaw, 1803) together with 15 
other species and 3 subspecies (Tesch, 1991). The (sub)species within this genus show 
a high degree of mutual resemblance with notable external characteristics such as the 
very elongated body, dorsal and anal fins confluent with a rudimentary caudal fin and 
12 
General introduction 
absence of pelvic fins. Anguilla spp. are usually distinguished by their geographical 
distribution, possibly in combination with their number of vertebrae or myomeres. Other 
common determination features are the colour of the skin, length of the dorsal fin, and 
construction of the jaws, including implant of the teeth. However, the latter features are 
age-dependent and can therefore only be used to discern individuals of approximately 
the same age. 
Figure 1. Different developmental stages of the European eel (Anguilla anguilla L., 1758). (a) 
Leptocephalus (from Tesch, 1983); (b) glass eels (from Usui, 1991); (c) yellow eel; (d) silver eel (from Tesch, 
1991). 
Wild European eel is supposed to spawn in the Sargasso Sea (26° N.lat. and 60° 
W.long.) at great depth with a peak spawning activity in March. This hypothesis is 
based on a spatial and temporal gradient in the size of caught eel larvae, the so-called 
leptocephali (Figure la). The exact spawning site is still unknown as sexually mature 
eels or fertilized eggs have never been found. During about 1 to 2.5 years the 
leptocephali migrate both actively and passively in the direction of the European and 
North African coast and finally metamorphose into the transparent glass eels (Figure 
lb). Except for the pigmentation, the eels now have almost attained their final 
13 
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appearance. The arrival of glass eels in estuaries and coastal waters depends on the 
distance of the particular coastal region from the spawning area. Once in fresh water, 
upstream swimming and feeding starts and a black pigmentation develops; these young 
eels are now called elvers. As pigmentation progresses, their colour gradually turns 
more or less yellowish and the yellow eel stage (Figure lc) is reached. Yellow eels may 
stay in fresh water for many years. During this period the sexual differentiation of the 
animals starts, but they do not attain sexual maturity. After at least 4 to 5 years, 
depending on sex and associated size, the eels gradually transform into silver eels 
(Figure Id). In this stage the fish morphologically and physiologically adapts to the 
upcoming return to the deep-sea spawning grounds. Clear external changes are 
development of a ventrally spreading silvery glow on the flanks and enlargement of the 
eyes. Besides, endocrine changes, growth of the gonads, migratory restlessness and 
cessation of feeding together with degeneration of the digestive tract have been reported. 
Eels are assumed to return to their parent spawning area, to spawn once and die. 
Figure 2. Map showing the natural geographic distribution of the European eel (Anguilla anguilla L., 1758; 
indicated by the shaded area) and the location of the supposed spawning grounds in the Sargasso Sea 
(indicated by an asterisk; after Tesch, 1983). 
14 
General introduction 
The natural geographic distribution of the inland stages ranges from the North Cape 
to the Atlantic coast of Morocco and the Canary Islands, and from the Black Sea to 
Iceland and the Azores (Figure 2). The distribution area is limited by the need to ascend 
from the sea. Thus, drainage areas directly connected to the Atlantic Ocean are 
favoured. Most conspicuous are the broad tolerance ranges with respect to environmental 
circumstances. Eels inhabit the cold northern European waters, whereas temperatures of 
up to 36° C are survived for at least several days (Schippers et al, 1991). As eels are 
euryhaline fish, they can be transferred smoothly from fresh to salt water and vice versa. 
If protected from drying out, they even survive outside the water. The eels live purely 
solitary and, dependent on their size, mainly predate on fish, oligochaetes or arthropods. 
However, as a result of their high fat content, they endure starvation for a considerable 
time. 
Willemse (1979) studied the internal morphology of the European eel. Although 
usually in a more elongate shape, the regular organs of teleost fish are present (Figure 
3), including the major lymphoid organs such as head and trunk kidney, spleen and 
thymus. Remarkable is the presence of a Y-shaped stomach, a large gallbladder and a 
prominent urinary bladder as well as the location of the kidney. The greater part of the 
excretory kidney (the trunk kidney) is situated postanally. At the rostral end the trunk 
kidney gradually changes into long, thin strands on both sides of the dorsal aorta. 
Histological investigations at our laboratory showed that the paired kidney strands 
consisted almost exclusively of lympho-myeloid tissue (not shown), suggesting 
homology with the much more rounded and rostrally situated head kidney (pronephros) 
in other teleosts. The excretory kidney of fresh water adapted eel contained, next to 
interrenal haematopoietic tissue, relatively few glomeruli, with long tubules compared 
to stenohaline fresh water fish. 
Culture of European eel 
According to the latest figures, the world aquaculture production of Anguilla spp. 
is about 105 metric tonnes (MT) yearly (Anonymous, 1994). The major part is produced 
in Japan and Taiwan and consists mainly of Japanese eel {Anguilla japonica Temminck 
and Schlegel, 1846). Culture of European eel is concentrated in Europe and totals about 
7-8-103 MT per annum. Eel culture in Japan and Europe was reviewed by Heinsbroek 
(1991). 
15 
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General introduction 
After the first attempts to raise eels under controlled circumstances were made in 
Europe, commercial eel culture actually started in Japan at the end of the last century. 
The initially primitive culture techniques have gradually been replaced by intensive 
culture methods. Nowadays, a production of about 40-103 MT of eels per year is 
realized only in Japan (Anonymous, 1994). The majority of the eels (80-90%) is raised 
in greenhouse ponds at densities of 5-20 kg-m"2 and temperatures of 22-28°C. Water 
quality is maintained by aeration and partial water exchange with fresh well water. 
Accordingly, stocked glass eels reach the marketable size of 150-200 g in about 1-1.5 
year. 
Eel culture in Europe has its origin in the Mediterranean area, notably Italy. This 
country is still the most important producer of European eel. Their culture is based on 
low-intensity aquaculture in brackish water lagoons. However, since the sixties a shift 
towards more intensive freshwater culture, using adapted Japanese farming techniques, 
is observed. 
The attractive market prices of eels, caused by declining catches (Tesch, 1991; 
Buijse et al, 1992) in combination with a high demand, have also created a strong 
interest in eel culture in north-western Europe. First, culture in heated effluents was 
attempted, but, due to disappointing results, this form of eel culture is declining. About 
two decades ago, the development of water recirculation systems for intensive culture 
of warm water species gave the opportunity for a new type of eel culture, which 
presently covers circa 30% of the eel culture production in Europe. These closed 
systems are stocked with glass eels or farm-raised elvers. The animals are frequently 
graded (every 1-4 month) and as their size increases they are transferred to larger tanks 
and stocked at higher densities (up to 75 kg-m"2). The water temperature is kept at 20-
25°C and feeding is almost exclusively done with compound feeds, either in pelleted or 
in paste form. Under these circumstances it takes about 1.5-2 years until the fish can be 
harvested (150-200 g), which is somewhat longer than the time needed to raise Japanese 
eels. This discrepancy is attributed to a lower growth performance of the European 
species (Tesch, 1983; Heinsbroek, 1991). 
In spite of partly successful attempts for artificial reproduction of eels (Yamauchi 
et al, 1976; Boëtius and Boëtius, 1980), production of glass eels in captivity is still not 
possible. Therefore, farming of eels totally depends on collection of wild, non-
domesticated stocking material. Especially in the initial culture phases, growth and 
survival are severely affected by non-acceptance of feed and infectious diseases 
17 
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(Heinsbroek, 1989). This may be connected with possible import of pathogens (Tesch, 
1991) and stress associated with the culture conditions (Peters et al, 1980), the latter 
also being a major cause for disease problems in the more advanced culture phases. 
Numerous pathogens have thus far been isolated from cultured eels (Reichenbach-
Klinke, 1980), however only few appear to be of importance with regard to clinical 
diseases. Next to some ectoparasitic infections caused by e.g. Dactylogyrus spp., 
Pseudodactylogyrus spp. and Trichodina spp. (Heinsbroek, 1991), bacterial diseases, 
which often start as opportunistic infections, may become very serious (Tesch, 1991). 
Koops and Kuhlmann (1983) even claimed that antibacterial drugs are indispensable for 
successful production in intensive eel aquaculture. 
Antibacterial drugs 
Antibiotics are chemical substances produced by various species of micro-organisms 
that either suppress the growth of other micro-organisms (bacteriostatic) or even kill 
them (bactericidal). Those with selective toxicity towards bacteria without interfering 
with the biochemical pathways of eukaryotic cells are of potential value in the therapy 
of bacterial diseases. Originally, a distinction is made between chemical synthetic drugs 
with antibacterial properties (chemotherapeutic agents) and antibiotics. However, this 
difference has lost significance as most antibacterial drugs are largely or entirely 
synthetic at present. Therefore, and because it enables to refer to both types in one go, 
the term antibacterial drugs is preferred in this thesis. 
The quantity of antibacterial drugs used in aquaculture on a worldwide basis is not 
available due to lack of control and record-keeping in most countries. In this respect 
Norway appears to apply the closest control because all drug use in veterinary medicine, 
including drugs used in aquaculture, is recorded by a few nationally authorized drug 
dispensing agencies. Figure 4 shows the total amount of antibacterial drugs used in 
Norwegian salmonid farming from 1980 until 1992 (Grave et al, 1990; Martinsen et al, 
1993). Taking the stock expansion during this period into account, there is still an 
increase from about 200 gMT"1 farmed fish in 1980 to about 600 g-MT'1 in 1987 
(Grave et al, 1990). Thereafter, these figures gradually returned to the amount reported 
for 1980 (Martinsen, 1993; Anonymous, 1994). The initial increase in drug use was 
caused by a high morbidity due to bacterial infections and development of drug 
General introduction 
resistance. The following decrease was attributed to an effective vaccination programme 
against Vibrio salmonicida and a tendency to cyclic variation in the utilization of drugs 
(Grave et al, 1990), but will also be affected by a shift to more potent drugs with lower 
doses per treatment. Notwithstanding the reduction in the last years, the total amount of 
antibacterial drugs needed to maintain the currently about 150xl03 MT of salmonids in 
Norway is still considerable. Realizing that these data are difficult to extrapolate to other 
countries and fish species, they give at least an indication of the extent in which 
antibacterial drugs are used in intensive finfish production systems. 
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Figure 4. The use of antibacterial drugs in treatment of farmed salmonids in Norway in the period from 
1980 to 1992. After data from Grave et ai (1990) and Martinsen (1993). Abbreviations: FZ, furazolidone; 
TMP/SDZ, trimethoprim/sulphadiazine; OTC, Oxytetracycline; OA, oxolinic acid; FQ, flumequine. 
The undesirably high amounts of antibacterial drugs used in intensive aquaculture 
may be illustrated by comparison with the prescription of such drugs in human and 
traditional veterinary (mainly cattle, swine and poultry) medicine. For the Dutch 
situation in 1990, Van den Bogaard et al. (1994) estimated that these antibacterial drug 
consumptions were 0.20 and 0.27 mg-kg^day'1, respectively. Making this calculation 
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for the use of antibacterial drugs in Norwegian salmonid farming in the same year 
(assuming that the FAO production data for 1991 (Anonymous, 1994) represent the 
biomass of farmed salmonids in the preceding year) revealed 0.80 mg-kg^day"1. This 
is about 3 times higher than the amount used for intensively cultured traditional farm 
animals. Although this difference may partly be explained by the difficulty of 
administering a sufficient amount of a drug to the right fish, the figures suggest that a 
reduction of the prescribed quantity of drugs for fish may be possible. In this respect, 
progress may be achieved by the availability of drugs tailored for use in aquaculture, 
which will enable more effective treatment. 
In The Netherlands, drugs specifically licensed for use in aquaculture are not 
available as yet. Nevertheless, drugs are regularly used for disease control at Dutch eel 
farms. Anthelmintics, mainly mebendazole, is used for the control of gill flukes 
(Dactylogyrus spp. and Pseudodactylogyms spp.). Furthermore, bacterial diseases, 
mainly caused by the opportunistic, Gram-negative bacteria such as motile Aeromonas 
spp. and Flexibacter spp., are predominantly controlled with the antibacterial drugs 
flumequine, Oxytetracycline and furazolidone. As the use of the latter drug is strongly 
discouraged in many countries and will probably be prohibited in the future, this thesis 
mainly deals with flumequine, while Oxytetracycline, one of the most extensively studied 
drugs in fish, is sometimes used as reference. 
(b) 
OH O OH O 
O H N K C H ^ 
Figure 5. The chemical structure of (a) flumequine (9-fluoro-6,7-dihydro-5-methyl-l-oxo-lH,5H-
benzo[ij]quinolizine-2-carboxilic acid) and (b) Oxytetracycline (4-(dimethylamino)-l,4,4a,5,5a,6,l 1,12a-
octahydro-3,5,6,10,12,12a-hexahydroxy-6-methyl-1,11 -dioxo-2-naphthacenecarboxamide). 
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Flumequine 
Flumequine (Figure 5) is a completely synthetic antibacterial drug and belongs to 
the so-called second generation quinolones. Like all quinolones flumequine was derived 
from nalidixic acid, the first clinically useful agent in this class of antibacterial drugs, 
which was originally isolated by Lesher et al. (1962). Flumequine was an important 
compound in the evolution of quinolones because of the introduction of a fluorine 
residue in the molecule, which enhanced and broadened the antibacterial activity 
compared to the previously available, non-fluorinated congeners (Andriole, 1988). It is 
a bactericidal agent, active against mainly Gram-negative bacteria (Smith and Lewin, 
1988; Anonymous, 1989; Mevius, 1990). Table 1 presents minimum inhibitory 
concentrations (MICs) of flumequine for different fish pathogenic bacteria as described 
in literature (Ceschia et al, 1987; Ledo et al, 1987; Martinsen et al, 1992; Palmer et 
al., 1992). 
The exact mode of action is still poorly understood (Crumplin, 1988; Diver, 1988). 
However, it is generally accepted that quinolones inhibit DNA synthesis by inhibition 
of the enzyme DNA-gyrase (Cozzarelli, 1980; Shen and Pernet, 1985; Wolfson and 
Hooper, 1985; Smith, 1986; Smith and Lewin, 1988; Drlica et al, 1990; Vancutsem et 
al, 1990). This is a bacterial type II topoisomerase and plays a crucial role in the 
unwinding, cutting and consecutive resealing of DNA. Inhibition of this enzyme results 
in filamentation of the bacterial cells, followed by vacuolization and ultimately death 
and lysis of the cells (Sonstein, 1990). Although it is known that active protein synthesis 
is required for these drugs to kill bacteria (Smith and Lewin, 1988), the actual lethal 
event is still unclear. Smith (1986) proposed that inhibition of the DNA resealing leads 
to exposed DNA nicks inducing exonuclease production, which in turn degrade the 
chromosomal DNA and consequently cause bacterial death. According to another 
hypothesis the bacteria are killed as a result of extensive induction of their own DNA 
repair system, and the ensuing gross alteration of the cell's biochemistry and 
morphology (Diver, 1988; Sonstein, 1990). Moreover, it has been suggested that 
quinolones have a second site of action, possibly the cell membrane, which contributes 
to cell death (Dougherty and Saukkonen, 1985; Chapman and Georgopapadakou, 1988). 
Very unusually among antibacterial drugs, the quinolones are not affected by 
plasmid-mediated resistance (Courvalin, 1990). As a consequence of this the frequency 
of clinical resistance to quinolones is much less than that of other major groups of 
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antibacterial drags (Smith and Lewin, 1988). Resistance to quinolones can only result 
from chromosomal mutations (non-transferable) that either diminish the affinity of the 
bacterial DNA-gyrase for the drug or decrease drug penetration into the cell (Barry, 
1990; Lewin, 1992). Nevertheless, the increasing use of quinolones in aquaculture has 
led to development of resistant strains of fish pathogenic bacteria. Moreover, both 
mutual cross-resistance among quinolones and co-resistance to other structurally 
unrelated drugs have been reported in laboratory-derived mutants as well as in strains 
isolated from diseased fish (Tsoumas et al, 1989; Barnes et al, 1990; Lewin et al, 
1992; Martinsen et al, 1992). 
Table 1. Minimum inhibitory concentrations (MICs) of flumequine for different fish pathogenic bacteria 
Bacterial species MIC (ng-mr) Reference 
Gram-negative bacteria 
Aeromonas caviae 
Aeromonas hydrophila 
Aeromonas salmonicida 
Aeromonas sobria 
Edwardsiella tarda 
Lislonella anguillarum* 
Pasleurella piscicida 
Pseudomonas fluorescence 
Pseudomonas pulida 
Vibrio carchariaiae 
Vibrio damsela 
Vibrio ordalii 
Vibrio salmonicida 
Vibrio tubiashii 
Yersinia ruckeri 
Gram-positive bacteria 
Enterococcus seriolicida* * 
Staphylococcus epidermis 
Streptococcus iniae 
<0.075 
O.075 
<0.01 - 0.78 
<0.075 
<0.01 - 0.3 
<0.01 - 0.3 
0.01 - 1.56 
3 - 6.25 
1.56 
0.3 
0.075 
3 
0.01 - 0.48 
1 
0.075 -0.312 
50 - >100 
1.56 -6.25 
25 - 50 
Ledo 
Ledo et al. (1987) 
Ledo étal. (1987) 
Palmer et al (1992) 
Ledo et al. (1987) 
et al. (1987); Palmer et al. 
Ledo et al. (1987); Palmer et al. 
Palmer et al. (1992) 
Ledo et al. (1987); Palmer et al. 
Palmer et al. (1992) 
Ledo et al. (1987) 
Ledo et al. (1987) 
Ledo et al. (1987) 
Martinsen et al. (1992) 
Ledo et al. (1987) 
Ledo et al. (1987); Ceschia et al 
Palmer et al. (1992) 
Palmer et al. (1992) 
Palmer et al. (1992) 
(1992) 
(1992) 
(1992) 
(1987) 
Formerly named Vibrio anguillarum; ** Formerly named Streptococcus seriolicida. 
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Flumequine was introduced into human medicine in the seventies. It has been used 
on a small scale, mainly for treatment of urinary tract and enteric infections (Rohlfing 
et al, 1976; Rohlfing et al., 1977). Today, this drug has only minor significance for 
human medicine due to the limited therapeutic utility and the availability of much more 
potent newer quinolones (Siporin, 1989; Vancutsem et al., 1990). 
Since the early eighties flumequine has been applied for fish disease control (Michel 
etal, 1980; Chevalier etal., 1981; Rodgers and Austin, 1983; Scallan and Smith, 1985; 
Takahashi et al., 1990; Alderman and Michel, 1992) and its use is still increasing (cf. 
Figure 4). Flumequine is often used as a substitute for the non-fluorinated quinolone 
oxolinic acid, which penetrated the aquaculture market about 10 years earlier (Endo et 
al, 1973a; Endo et al, 1973b). At first, this shift will have been based on observed 
differences in clinical responses. However, an increasing number of laboratory studies 
demonstrated a higher in vitro antibacterial activity of flumequine for bacterial fish 
pathogens (Ledo et al, 1987; Nakano et al, 1989; Barnes et al, 1991; Barnes et al, 
1992; Martinsen et al, 1992; Palmer et al, 1992). Moreover, comparative studies in 
Atlantic salmon showed that flumequine possesses more appropriate pharmacokinetic 
properties in this species (Martinsen et al, 1993; Rogstad et al, 1993). 
Oxytetracycline 
Oxytetracycline (Figure 5) is produced by strains of Streptomyces spp. and was first 
isolated by Finlay et al (1950). This agent belongs to the group of tetracyclines and was 
the first true broad spectrum antibiotic, effective against a wide range of micro-
organisms including Gram-positive and Gram-negative bacteria, Rickettsiae, Mycoplasma 
and Chlamydia. Oxytetracycline is a bacteriostatic drug, inhibiting prokaryotic protein 
synthesis by binding to the 30 S sub-unit of the bacterial ribosomes and thus preventing 
addition of amino acids to the growing peptide chain (Sande and Mandell, 1985). 
Shortly after the introduction into human medicine, it appeared that Oxytetracycline 
could also be effectively used in fish culture (Alderman, 1988). Thus this drug rapidly 
became the drug of choice in treatment of bacterial fish diseases. The frequency of 
Oxytetracycline resistant bacterial strains has increased dramatically since its first 
application. Presently, the mainly R-plasmid associated tetracycline resistance is the 
most common resistance determinant among all bacterial species. In addition, exposure 
to tetracyclines may lead to co-resistance against other, chemically unrelated, 
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antimicrobial drags (Levy, 1984). These unfavourable properties, together with the 
availability of more potent antibacterial drugs, will have played a crucial role in the 
declining utilization of this drug (Samuelsen, 1993). 
Pharmacokinetics 
Baggot (1977) defined pharmacokinetics as the mathematical description of 
concentration changes of drugs (and/or their metabolites) within the body following 
administration. A common approach for studying the pharmacokinetic behaviour of 
drugs is to depict the body as a system of distribution compartments. The latter are 
theoretical entities, usually without a clear physiological meaning. The number of 
compartments needed to adequately describe the disposition of a drug is dependent upon 
the course of the drug concentration in a particular situation. The body may be regarded 
as a single compartment if a drug distributes and equilibrates immediately between the 
different tissues. For other situations a 2 or more compartment model has to be used. 
In many instances the two-compartment open model (Figure 6) appears to be suitable 
(Baggot, 1977). It is assumed that a drug entering the body distributes instantaneously 
and homogeneously into the central compartment. For many drugs this consists of the 
blood plasma and extracellular fluid of readily accessible (highly perfused) organs. 
Distribution into the less well-perfused parts of the body, the peripheral compartment, 
is more slowly. Simultaneously, elimination (i.e. biotransformation and excretion) of the 
drug takes place from the central compartment. 
In fish, like in other organisms, the fate of a drug is determined by its absorption, 
distribution and elimination. Besides being interdependent, these processes are affected 
by a variety of factors (Rasmussen, 1988; Ingebrigtsen, 1991; Nouws et al., 1992), 
which may largely be classified as physico-chemical characteristics of the drug (e.g. 
ionization, molecular size and solubility), intrinsic factors related to the host (e.g. 
biotransformation and excretion capacity) and environmental circumstances (e.g. water 
temperature and salinity). The importance of the latter has to be emphasized, because, 
unlike in homeothermic animals, the physiological conditions for drug absorption and 
disposition in fish vary considerably depending on the environment (Smit et al., 1981; 
Ishida, 1992). In particular the influence of temperature on pharmacokinetic parameters 
deserves special attention (Bjórklund et al., 1992; Sohlberg et al., 1994). In fish and 
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other Poikilothermie animals, body temperature and associated metabolic rate hinge on 
ambient temperature (Ellis et ai, 1978). Therefore, biotransformation and active 
(excretion) processes are usually enhanced at higher temperatures. Furthermore, 
temperature interferes with translocation of drugs through an effect on membrane 
composition and blood flow. 
Administration 
O 
CENTRAL 
COMPARTMENT 
Elimination 
Distribution => / PERIPHERAL COMPARTMENT 
Figure 6. Concept of the open two-compartment model. After administration, the drug enters the system 
via the central compartment, where it distributes instantaneously. Distribution between central and peripheral 
compartments takes place more slowly. Elimination, which comprises biotransformation and excretion, is 
assumed to occur exclusively from the central compartment (adapted from Baggot, 1977; Ritschel, 1992). 
Differences between fish species with regard to anatomy and physiology are often 
underestimated. Despite obvious similarities among these animals, mainly enforced by 
the characteristics of the aquatic environment, the wide variety of habitats that have 
been occupied, and the associated specific adaptations, account for a large diversity 
within this group. Resulting species-dependent differences in pharmacokinetics implicate 
that extrapolation of data from one fish species to another may be invalid (Ingebrigtsen, 
1991; Nouws et ai, 1992). This may be illustrated by the plasma concentration versus 
time curves of intramuscularly injected Oxytetracycline in three warm water species as 
shown in Figure 7. Except for the indicated temperatures, identical experimental 
conditions and analytical methods were employed. Most striking is the deviant 
elimination rate of the drug in European eel (Anguilla anguilla L.,1758; t,A=215 h) 
compared to common carp (Cyprinus carpio L., 1758; t,/2=78.6 h) and African catfish 
(Clarias gariepinus Burchell, 1822; t1/2=74.4 h), which can not be explained by the 
differences in ambient temperature alone. 
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Figure 7. Mean concentrations of Oxytetracycline (OTC) in plasma of common carp (Cyprinus carpio L., 
1758) at 20 °C, African catfish (Clarias gariepinus Burchell, 1822) at 25 °C and European eel (Anguilla 
anguilla L., 1758) at 22 °C following a single intramuscular injection of 60 mg-kg"1 body weight. * Data from 
Grondel et al, 1987a; ** data from Grondel et al, 1989; **• data from Nouws et al, 1993. 
At present the available pharmacokinetic data of drugs in fish are limited. However, 
an increasing attention for this subject is observed in recent years, which is probably due 
to the rapidly growing need for safe and effective disease treatment methods in 
aquaculture (Schnick, 1992). The research is concentrated on the economically most 
important species (mainly salmonids), while species with a more regional, minor 
significance receive relatively little attention. Consequently, in general the scientific 
basis for the use of drugs in aquaculture is still insufficient. Therefore, treatment regimes 
and withdrawal periods are necessarily often based on those used in homeothermic 
animals (Boon et al, 1991). This is an undesirable situation, because pharmacokinetic 
parameters may differ profoundly between fish and mammals or birds (Grondel et al, 
1986; Nouws et al, 1986; Ingebrigtsen, 1991). 
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The immune system of teleost fish 
Like other vertebrates, fish possess an extensive defence system, which enables the 
individual to survive and maintain its integrity in a hostile environment. The protective 
mechanisms are directed against foreign material recognized as non-self, including 
pathogens and malignant cells, and comprise a number of innate (non-specific) and 
adaptive (specific) reactions. The defence system of fish seems to be less complex than 
that of higher vertebrates (Ellis, 1982; Ratcliffe and Millar, 1988), but it will be very 
well adapted to the aquatic environment by natural selection during more than 350 
million years. Although the immune system of fish is still less unravelled, the functional 
and morphological similarities with its mammalian counterpart are obvious. 
Correspondingly, fish contain most, if not all, of the different types of leucocytes found 
in mammals (Rowley et al, 1988). 
The non-specific immunity is characterized by the absence of an enhanced reaction 
after repeated infection (no memory formation) and the non-specific character. The non-
specific defence in teleosts may be arranged according to the successive lines of defence 
encountered by invading substances (Lamers, 1985). In this way, the first line of defence 
comprehends the relatively stable physical and chemical barriers, which prevent 
penetration of foreign material into the host or eliminate these substances immediately 
after penetration. The epithelia, their secretions and several secreted and/or excreted 
protective (glyco)proteins (e.g. precipitins, agglutinins and lytic enzymes) are the most 
important factors in this line. The second line of non-specific defence consists of those 
processes that are more or less inducible upon infection. The cells involved are non-
specific cytotoxic cells besides phagocytosing monocytes/macrophages and granulocytes. 
In addition, substances like complement factors and anti-viral and acute phase proteins 
play an important role at this stage. 
Specific immune responses (accomplished by the immune system in its strict sense), 
which may be regarded as a third line of defence, include the reactions of lymphoid 
cells besides the cellular and humoral components that are related to the response of 
these cells. This form of defence is typified by antigen specificity and memory 
formation, which finds expression in an enhanced response after repeated contact with 
the same antigen. In teleost fish, the mechanisms involved in specific immunity seem 
to be essentially the same as in mammals and can accordingly be subdivided into 
cellular and humoral responses (Rijkers, 1981; Secombes, 1991). Likewise, strong 
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indications are available by now for the existence of mucosal immune responses in 
teleosts (Rombout et al, 1993a; Rombout et al, 1993b). 
Humoral immune responses involve antigen uptake from the circulation or mucosae, 
followed by processing and presentation of the antigen by macrophages to antigen 
sensitive lymphocytes. Under influence of rather complex interactions between distinct 
leucocyte (sub)populations and immunoregulatory factors (cytokines; Secombes, 1991) 
produced by the interacting cells, B-lymphocytes proliferate and differentiate into 
antibody (immunoglobulin; Ig) secreting plasma cells. The specific antibody binds to the 
antigen, which can subsequently be eliminated by way of several mechanisms (Roitt et 
al, 1993). Teleost fish produce only one class of Ig (physico-chemically resembling 
mammalian IgM), which however functionally mimics several mammalian Ig classes 
(Ellis, 1982). 
Cell mediated immunity is attributed to the activity of a T-lymphocyte subpopulation 
termed cytotoxic T cells and it implies lysis of cells, recognized as non-self, by cell to 
cell contact. This mechanism plays a role in resistance against, for instance, virus-
infected and neoplastic cells and in graft rejection. After activation, initiated by 
recognition of antigen expressed on cell membranes, T-lymphocytes can either act as 
cytotoxic T cells or as regulatory cells in humoral and cellular responses (T helper cells) 
by producing appropriate cytokines. Regulation and control of T-lymphocyte activation 
in teleosts is ascribed to a regulatory system analogous or homologous to the 
mammalian histocompatibility complex (Stet and Egberts, 1991). At present, different 
T-lymphocyte types are functionally characterized in several teleost species but they can 
not be well identified immunocytochemically because monoclonal antibodies, reactive 
to specific T cell membrane markers, are still not available (Koumans-van Diepen, 
1993). 
Immunomodulation 
Immunomodulation is a consequence of a change in quantity and/or function of cells 
or substances involved in non-specific or specific immune responses. It thus concerns 
induction, blocking, amplification or inhibition of consecutive steps in defence reactions. 
Strictly speaking, the reactions against an antigen, which may imply both active immune 
responsiveness and tolerance, as well as the tuning of these responses by 
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immunoregulatory mechanisms, may be interpreted as immunomodulation. Moreover, 
the immune capacity of Poikilothermie animals like fish, is highly dependent on ambient 
temperature. Within the temperature range of the species, higher temperatures usually 
enhance the response, while lower temperatures are suppressive (Rijkers et al., 1980a). 
However, in the present thesis the term immunomodulation is used in connection with 
immunotoxicological events, which affect the defensive potential or the actual 
functioning of the defence system. This may result from any interference of foreign 
agents with the immunocompetent cells or the complexly organized communication 
between them. Disturbances may lead to immunosuppression, which negatively affects 
the health of the host by creating a deficient resistance to diseases. Conversely, 
stimulation of the defence system may also occur. This phenomenon obviously holds 
great potential for practical applications in disease prevention (Anderson, 1992; 
Onarheim, 1992). 
Modulation of the defence system of fish may result from the action of 
environmental factors on critical physiological pathways. Depending on timing, duration 
and dose, exposure to ionizing radiation (Cosgrove et al., 1975; Fabacher et al., 1994) 
and environmental pollutants, such as pesticides and metal ions (Dunier, 1994) have 
frequently shown to impair fish immune systems. Until recently, relatively few 
experiments have been described in which immunostimulation was concerned. Most 
reports deal with adjuvants that have been added to fish bacterins to augment the 
intensity of the reaction, to increase the speed, and to prolong the duration of the 
specific immune response. However, there is an increasing interest in products that can 
be given alone (i.e. without simultaneous antigenic stimulation) and additionally induce 
a more generalized protection by boosting non-specific defence mechanisms. Special 
attention is paid to natural substances like glucans, which can be administered as feed 
additive and which may be easily certified by governmental agencies (Anderson and 
Siwicki, 1994). 
Another category of possible immunomodulating substances is formed by the drugs 
used for prophylaxis and treatment of fish diseases. Antibacterial drugs are by far the 
most important drugs used in fish culture. Until about a couple of decades ago, 
surprisingly little was known about interactions of these drugs with defence mechanisms. 
Previously it has always been taken for granted that antibacterial drugs help the 
organism in its fight against infection by killing bacteria or suppressing their growth. 
By now, many reports have described either positive, negative or no effects at all of 
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antibacterial drugs on different aspects of the defence system (Grondel and van 
Muiswinkel, 1986). However, it is difficult to draw general conclusions because the 
picture is based on effects of different drugs studied in many animal species by means 
of a variety of tests. Moreover, the exact mechanisms of immunomodulation are often 
unknown or poorly understood (Van Loveren and Vos, 1991). 
Only a limited number of studies is available concerning the effects of antibacterial 
drugs upon protective mechanisms and the associated health in fish. Immunomodulating 
characteristics of Oxytetracycline, probably the most extensively studied drug in this 
respect, were investigated in common carp {Cyprinus carpio L., 1758). Injections with 
this drug significantly prolonged the survival of allografts (Rijkers et al, 1980b). 
Grondel and Boesten (1982) found that the in vitro mitogenic response of leucocytes 
from several lymphoid organs to T cell mitogens showed an oxytetracycline-dependent 
decrease confirming the effect of this drug on T cell functions. Moreover, a suppressive 
effect of Oxytetracycline on the in vivo humoral response in carp was described by 
Rijkers et al. (1980b; 1981) at the level of antigen binding and antibody producing cells. 
Numbers of antibody producing cells were reduced up to 95% during a primary 
response, while secondary responses were not significantly inhibited. Later it was 
demonstrated that the effect on the humoral response was more a delay than a 
suppression (Grondel et al, 1987b). Negative effects of Oxytetracycline on antibody 
production were also demonstrated in rainbow trout (Oncorhynchus mykiss Walbaum, 
1792), whereas a potentiated sulphonamide (Ro5-0037), tested by the same regimes, did 
not affect this mechanism (Anderson et al, 1984). 
Grondel et al (1985) tested various concentrations of several other antibacterial 
drugs for their possible interference with the mitogenic response of isolated pronephric 
leucocytes from carp in an in vitro system (Figure 8). From the results it can be 
concluded that the effect of most drugs is concentration-dependent. For different drugs 
either stimulation or suppression of the mitogenic response was observed. Moreover, 
some drugs were stimulators at lower concentrations whereas at higher doses they 
became suppressive. Taking into account that the distribution of antibacterial drugs 
across the body may be heterogeneous, depending on for instance the composition and 
blood perfusion of the tissues/organs and the biochemical characteristics of the drug 
(Ritschel, 1992), critical drug concentrations may be reached at immunologically 
important sites. Accumulation of a drug in particular tissues/organs may increase the 
probability for the emergence of lesions in the organs involved. For example Grondel 
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Figure 8. Several antibacterial drugs were tested for their possible interference with DNA synthesis. 
Phytohaemagglutinin-activated pronephric leucocytes from common carp (Cyprinus carpio L., 1758) were 
cultured for 4 days in the absence or presence of varying concentrations of different antibacterial drugs. The 
results of triplicate cultures are expressed in percentage stimulation or inhibition compared with mitogen-
treated control cultures, 'injectable, 2powder and * not tested (after Grondel et ai, 1985). 
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et al. (1987a) showed that Oxytetracycline is accumulated and retained in scales, bone 
and lymphoid tissues in common carp. They suggested that the negative influence of 
Oxytetracycline on carp immune responses may be related to the specific affinity of this 
drug for lymphoid tissues. 
Immunomodulation can also be caused by an indirect effect of drug treatment on 
the defence system. For example drug interference with feed digestion or absorption 
may act upon the nutritional status and subsequently influence the animal's resistance 
(Blazer, 1992). Moreover, physical or chemical stress, which may result from drug 
treatment (e.g. handling of fish during the administration procedure or changes in water 
quality as a consequence of drug addition), is known to affect a variety of 
immunological parameters (Anderson, 1990). Stress initially affects the endocrine system 
by inducing higher levels of plasma Cortisol (Pickering, 1992). Since the immune system 
is under hormonal control, including corticosteroids, these changes may in turn lead to 
alteration of defence mechanisms (Ellis , 1981). 
As explained in the previous paragraph, immune responses are rather complex 
interactions between distinct leucocyte types and different cytokines, produced by the 
interacting cells. Therefore, major disturbances in immunological responses may result 
from a subtle modification at a crucial point. Still, resistance against an infection can 
be achieved by means of several routes and suppression or impairment of one route will 
not always lead to a recognizable pathology. Furthermore, different leucocyte 
populations may have a variable sensitivity to toxic agents. This complexity and 
multiplicity of immune responses often make a single test inadequate for evaluating 
immunomodulation and thus in most cases a battery of tests is recommended (Dunier 
et ai, 1994). Another approach, which also indicates the practical relevance of a 
possible immunomodulation, is the challenge with a pathogen. By using these 'real 
world' tests the defence system's function is more integrally addressed, as resistance 
against pathogens is generally based on a series of, often mutually dependent, non-
specific and specific protective mechanisms (Van Loveren and Vos, 1991). 
Indicator assays 
To monitor immunomodulation in fish many in vitro and in vivo immunological 
assays are available, which are mainly a result of adaptation of techniques originally 
developed for mammals. These assays can be divided into three broad categories (Table 
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2). The general assays are in vivo tests indicating the health of fish by measuring 
parameters that report the potential and global condition of the defence system without 
giving information about an effect on a specific immune mechanism. Except for the 
challenge test, these assays are normally used without antigenic stimulation. The assays 
of non-specific resistance used in fish mainly comprise tests for the functional activity 
of the cells involved in the non-specific defence or the initial steps of a specific 
response. These tests are carried out in vitro and can be used with and without prior in 
vitro or in vivo stimulation. The last category of immunomodulation indicator assays 
consists of both in vitro and in vivo tests that usually include antigenic or mitogenic 
stimulation and subsequent measurement of specific immune response mechanisms. 
Table 2. Selection of (immunological) indicator assays used to determine immunomodulation in fish 
Assay and/or parameter 
Specific 
modulation 
Reference 
(example) 
General assays 
Weight of lymphoid organs 
Haematocrit (blood cell level) 
Leucocrit (white blood cell level) 
Leucocyte differentials 
Total/differential plasma protein level 
Challenge with pathogen 
(host survival; pathogen recovery) 
Non-specific resistance assays 
Phagocytic index 
Chemiluminescence (oxidative activity) 
Cytotoxic cell activity 
None 
None 
None 
None 
None 
Protection against disease 
Endocytosis 
Phagocyte killing potential 
Natural cytotoxicity 
Anderson et at (1982) 
Elsaesser and Clem (1986) 
Pickering and Pottinger (1987) 
Blaxhall (1972) 
Holmberg et al. (1972) 
Houghton and Matthews (1986) 
Olivier el at (1986) 
Dunier el at (1994) 
Rougier et al (1994) 
Specific immune response assays 
Blastogenisis (mitogenic response; 
mixed leucocyte response) 
Allograft rejection 
Hemolytic plaque assay 
ELISPOT assay 
Agglutination 
ELISA 
Lymphocyte proliferation 
Cellular immunity 
Antibody production 
Antibody production 
Antibody production 
Antibody production 
Grondel et al. (1985) 
Rijkers et al (1980) 
Rijkers el al (1981) 
Dunier and Siwicki (1994) 
Grondel et al. (1987b) 
Rijkers et al. (1981) 
Modified from Anderson, 1990. 
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Specific immune responses and in particular the production of circulatory antibodies, 
are among the most frequently used determinants of immunomodulation. Indeed, 
measurement of the presence and amount of humoral antibodies include some of the 
most sensitive and fastest immunoassays with the added advantage that the results are 
often linked to the degree of protection against a specific disease (Anderson, 1990; Van 
Loveren and Vos, 1991). However, one should be aware that modulation of a specific 
response, which is measured in the final phases of an immune reaction, may be due to 
an effect on earlier processes in the sequence of defence mechanisms. 
The assessment of (functional) characteristics of the immune system generally 
benefits very much from the availability of monoclonal antibodies (mAbs) recognizing 
cell-specific membrane antigens or products. These mAbs are accurate and highly 
specific tools that can be used in several qualitative and quantitative tests, including 
microscopic and flow cytometric analyses of cells or enzyme-linked immunosorbent 
assays (ELISAs) for detection of certain (immunologically important) serum 
constituents. 
In recent years there is a trend towards the use of in vitro models for studying 
immunomodulation, which is aimed at a reduction of experimental animals and (toxic) 
test chemicals. Although this may be a valuable approach to study the mechanisms of 
immunomodulation, a serious drawback is the difficulty to extrapolate the results to the 
real in vivo situation. Under in vitro circumstances the complex interactions between the 
different cell types and cell products, which are characteristic for immune responses, are 
virtually lacking. Moreover, the actual changes of the concentration of a xenobiotic 
substance in an animal as a result of absorption and disposition processes, as well as 
possible metabolic activation of those substances, can not be implicated. In the present 
thesis preference is given to in vivo assays so as to obtain more relevant and readily 
applicable results for the aquacultural practice. 
Aim and outline of the thesis 
Application of antibacterial drugs has played and will certainly continue to play an 
important role in the control of bacterial diseases in intensive aquaculture. However, as 
yet the scientific basis for the use of these drugs is often lacking or incomplete. 
Research in this area is concentrated on the major species in large scale intensive 
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culture, notably salmonids. Attention is mainly paid to the pharmacokinetics and in vitro 
and in vivo efficacy of a number of drugs. For other species than those mentioned above 
the situation is generally worse. As yet in many cases the application of drugs is still 
based on empiricism and/or on knowledge from work with other, often unrelated fish 
species or even homeothermic farm animals. Investigations into safety issues, related to 
the use of antibacterial drugs, are limited to some residue studies and, more recently, a 
growing interest in the impact of drugs on the (still mainly marine) environment is 
observed. Only few studies deal with the effect of antibacterial drugs on fish health, 
although these drugs are known as potential immunomodulators. 
The current thesis intends to contribute to the comprehensive task of establishing 
rational criteria for the use of antibacterial drugs in fish, which ultimately may promote 
sound and effective medical management in aquaculture. The studies presented are 
focused on European eel, because of the economical importance of this species in a 
number of countries, including The Netherlands. With respect to the antibacterial drugs, 
emphasis is clearly put on flumequine. This drug is one of the most recently introduced 
drugs in eel culture, which is commonly used and expected to gain importance in the 
future. Within this framework, the attention is concentrated on possible drug induced 
immunomodulating effects and the associated influence on fish health. 
Positive as well as negative effects of drugs are partly dependent on the 
concentrations of the product and/or its possible metabolites in the host after 
administration. Accordingly, the first experiment described in this thesis deals with the 
kinetics of flumequine in 3 warm water fish species (chapter 2). Using a comparative 
approach, the plasma disposition of the drug was investigated in common carp (Cyprinus 
carpio L., 1758), African catfish (Clarias gariepinus Burchell, 1822) and European eel 
(Anguilla anguilla L., 1758) following a single peroral administration. For the latter 
species the pharmacokinetic research is continued with the work presented in chapter 
3. This chapter provides data on the distribution and residue elimination of flumequine 
in eel, which were obtained by determination of tissue levels of the drug after an 
intramuscular injection. 
Chapter 4 relates to the production and subsequent characterization of monoclonal 
antibodies (mAbs) to immunoglobulin of the European eel. Within the present research 
these mAbs were essential to accurately investigate the effect of drug-treatment on 
several immunological parameters. In the following experiments they are used to 
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identify and enumerate immunoglobulin bearing lymphocytes (B cells) and to determine 
the antibody response after infection. 
The interference of flumequine with the proliferative capacity of European eel 
lymphocytes is described in chapter 5. An in vivo lymphocyte stimulation 
(blastogenesis) assay was developed and attention was paid to the drug effect on both 
concanavalin A (Con A) and lipopolysaccharide (LPS) induced proliferation. 
Subsequently, in chapter 6 an available challenge model was used to study the 
influence of flumequine and also Oxytetracycline exposure on the overall condition of 
the eels defence system. The fish were experimentally infected with the parasitic 
swimbladder nematode Anguillicola crassus and the resistance against this infection was 
assessed on the basis of parasite recovery, numbers of different circulating leucocytes 
and specific antibody production. 
Finally, in chapter 7 the results of the preceding chapters are summarized and 
discussed in a broader context. Moreover, some recommendations for further research 
are indicated. 
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Abstract 
The disposition of perorally administered flumequine in plasma was compared 
between common carp (Cyprinus carpio L., 1758), African catfish (Clarias gariepinus 
Burchell, 1822) and European eel (Anguilla anguilla L., 1758) respectively, at a dose 
of 18 mg-kg"1 body weight. All species showed rapid absorption followed by biphasic 
plasma depletion. Significant interspecies differences were observed for most of the 
determined pharmacokinetic parameters. Mean highest plasma flumequine concentrations 
were 6136 ng-ml"1 in carp, 4074 ngml"1 in eel and 1179 ng-rnl"1 in catfish. Mean 
distribution and elimination half-lives were 3.4 and 104.3 h for carp, 7.3 and 59.5 h for 
catfish and 56.7 and 451.2 h for eel. To achieve equivalent drug efficacy and to 
minimize the probability of residues as a result of medication, dosage regimes and 
withdrawal periods should be adapted for each species. 
Key-words: Pharmacokinetics, Flumequine, Common carp, African catfish, European 
eel. 
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Introduction 
High stocking densities in intensive aquaculture result in an increased prevalence 
of infectious diseases. Administration of antibacterial agents is an effective means of 
controlling bacterial diseases in cultured fish (Gratzek, 1983). Nevertheless, there is a 
growing concern about the safety of fish medication to public health (Bernoth, 1991), 
the environment (Kupka Hansen et al, 1992) and target animals (Van der Heijden et al, 
1992). 
In many countries, legislation regarding the availability and use of medicinal 
products in aquaculture is inadequate, because they were formulated with 'conventional' 
veterinary medicine in mind (Alderman and Michel, 1992). However, marked 
differences between drug behaviour in fish and other phyla like mammals and birds are 
clearly demonstrated in literature. Most prominent is the often extended elimination half-
life of drugs in fish compared to homeothermic animals. This can be explained by the 
usually large differences in physiological, biochemical and morphological properties of 
those taxa (Nouws et al, 1986). Furthermore, external factors such as ambient 
temperature, pH and salinity influence the pharmacokinetics of most drugs in fish 
(Rasmussen, 1988; Björklund et al, 1992; Ishida, 1992). 
Pharmacokinetic data of fish are difficult to compare as a result of the variety of 
experimental conditions. In addition, various drugs, routes of administration and dose 
rates make proper comparative studies difficult. 
The present study compared the plasma disposition of flumequine, after a single 
peroral administration, in three important cultivated fish species in The Netherlands, 
namely common carp, African catfish and European eel. Flumequine is commonly 
applied for the control of bacterial diseases in these species. 
Materials and methods 
Fish 
Common carp (Cyprinus carpio L., 1758) and African catfish (Clarias gariepinus 
Burchell, 1822) were raised at the Wageningen Agricultural University (Huisman,. 1974; 
Hoogendoorn, 1983) without drug use while European eel (Anguilla anguilla L., 1758) 
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was obtained from a commercial eel farm, where the fish had not been treated with any 
antibacterial agent. 
Groups of 5 clinical healthy, non-sexed fish of each species, with a mean weight of 
451.2 + 118 g (carp), 382.6 ± 66.1 g (catfish) and 195.5 ± 33.0 g (eel), were used. The 
fish were acclimatized on a 12 h dark/12 h light photoperiod in a 150-litre aquarium 
with aerated tap water of 24 ± 1°C, pH 8.0 + 0.2 at a flow rate of 150 lh"1 for 14 days 
prior to the experiment. The fish were not fed during the acclimatization nor during the 
experimental period to avoid differences in drug kinetics as a consequence of differences 
in nutritional status. 
Individual fish were identified by a subcutaneously injected micro-transponder 
containing an unique code (Adam et al, 1992). 
Antibacterial treatment 
An aqueous solution of flumequine (Flumiquil®, premix consisting of 50% (w/w) 
pure flumequine, 20% (w/w) lactose and 30% (w/w) sodium carbonate; Pitman-Moore, 
Haarlem, The Netherlands) was prepared at a concentration of 4.5 rngml"1. Fish were 
sedated with Hypnodil® (0.3 ml l"1; Janssen Pharmaceutica B.V., Beerse, Belgium) for 
about 5 minutes and flumequine was administered perorally as a single dose of 18 
mg-kg"1 body weight by intubation of the stomach (catfish and eel) or the first gut 
segment (carp). 
Blood sampling 
The fish were sedated and 0.5 ml blood samples were collected from the caudal 
vein, with a heparinized syringe at 0, 2, 4, 8, 12, 16, 24, 48, 96, 144, 192, 336, 480, 
624, 768, 912 and 1056 h after administration of the drug. Blood samples were 
immediately placed on ice and subsequently centrifuged for 10 min at 1300xg and 5°C. 
Plasma was stored at -60°C pending analysis. 
Sample analysis 
The concentration of flumequine was determined in plasma, using the high 
performance liquid chromatography (HPLC) method as described in this section. 
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Furthermore, plasma samples with high flumequine levels (>1000 ng-ml"1) were 
analyzed for 7-hydroxy-flumequine and both glucuronidated flumequine and 7-hydroxy-
flumequine (Mevius et al, 1990). 
Standards 
Flumequine was purchased from Sigma Chemical Co. (St. Louis, MO, USA) and 
7-hydroxy-flumequine was obtained from Riker/3M (Zoeterwoude, The Netherlands). 
Stock solutions of 100 ug-ml"1 were prepared in 0.01 M sodium hydroxide. Working 
standard solutions were prepared by dilution with water. 
Reagents 
All chemicals were of analytical grade (Merck, Darmstadt, FRG). Subtilisin was 
purchased from Boehringer (Mannheim, FRG) and beta-glucuronidase/arylsulfatase from 
IBF (France). Subtilisin solution was prepared by dissolving 12.5 mg subtilisin in 100 
ml Tris buffer 0.1 M (pH 10). The HPLC eluent consisted of 660 ml 0.02 M o-
phosphoric acid, 200 ml acetonitrile and 140 ml tetrahydrofuran. A 0.001 M o-
phosphoric acid solution, passed through a chromatographic column (10x2 cm) filled 
with amberlite XAD-2 (0.3-0.78 mm; BDH, Dorset, UK), was used for flushing the on-
line concentration column. 
Instrumentation and chromatographic conditions 
The column-switching HPLC system consisted of a Gilson 231-401 automatic 
sampler (Gilson Medical Electronics, Villiers-le-Bel, France), two 6000A liquid 
chromatographic pumps (Millipore, Milford, MA, USA), a Rheodyne 7010 automatic 
sixport switching valve (Berkeley, CA, USA) and a Hitachi F 1050 fluorescence 
detector (Merck, Darmstadt, FRG). The analytical column was a 150x4.1 mm ID PRP-1 
column (Hamilton company, Reno, NV, USA). The concentration column (10x2.1 mm 
ID) was packed with Serdolit AD-4 0.05-0.1 mm (Serva, Heidelberg, FRG). 
The mobile phase flow was 1 ml min"1 and the sample enrichment flow was 0.8 
ml min"1. The fluorescence detector was operated at an excitation and emission 
wavelength of 315 nm and 360 ran, respectively. The timed event sequence for sample 
enrichment and separation was as follows: 0 min, injection and start flushing the 
concentration column; 4 min, activate sixport valve for backflushing the compounds of 
interest to the analytical column; 11 min, reset sixport valve and equilibrate the 
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concentration column with flushing solvent; 20 min, next injection. 
Sample preparation 
Frozen plasma samples were thawed and centrifuged for 5 min at 7000xg. Plasma 
(75 ui) and subtilisin solution (75 ul) were pipetted into a reaction vial and incubated 
for 20 min at 55°C. After cooling, 50 ul of the extract was analyzed by HPLC. 
Hydrolysis of conjugates 
A volume of 50 ul plasma was mixed with 150 ul buffer solution (pH 5). Following 
addition of 50 ul beta-glucuronidase the sample was incubated for two hours at 37°C. 
After cooling, 250 ul Tris buffer (pH 10) and 250 ul subtilisin solution were added. 
The mixed sample was incubated for 20 min at 55°C. After cooling, 100 ul of the 
extract was injected in the HPLC system. 
Method characteristics 
The mean recovery of flumequine after spiking blank plasma samples of the 
investigated species with 250 ng-ml"1, was 89.9% (CV=8.3%; n=12) and the correlation 
coefficient of the standard curve was 1.0000 over the range 1-10000 ng-ml"1. Recovery 
of 7-hydroxy-flumequine was in the same order of magnitude as found for flumequine 
(80-100%). 
None of 40 different drugs checked for interferences could be observed in the 
chromatograms. The limit of quantification was set at 2 ng-ml"1, corresponding to 
approximately twice the noise level for blank samples. 
Pharmacokinetic analysis 
Plasma flumequine concentrations of each fish were analyzed by curve stripping 
(Baggot, 1977) using PKCALC, a computer program for pharmacokinetic analysis 
(Shumaker, 1986). 
The highest flumequine concentration observed and the corresponding time after 
administration were read from the collected concentration versus time data of the 
individual animals. Total areas under the plasma drug concentration versus time curves 
(AUC) were determined by the linear trapezoidal rule in the PKCALC-program. 
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Statistical analysis 
Mean and standard error of the pharmacokinetic parameters were calculated. Wilk-
Shapiro/Rankit plots were used to examine whether the pharmacokinetic values of the 
individual animals per species conformed to a normal distribution. A Wilk-Shapiro 
statistic >0.900 was assumed for a normal distribution. Significance of differences in 
pharmacokinetic parameters between the species was tested with the two sample T-test 
in case of normality and otherwise by the non-parametric Wilcoxon rank sum test. For 
both tests a 90% confidence interval was used. 
All statistical analyses were performed with the computer program STATISTIX 
(1985). 
Results 
Typical chromatograms of standard solutions, blank and spiked plasma are shown 
in Figure 1. The highest plasma flumequine concentrations observed were 6136, 1179 
and 4074 ng-ml"1 for carp, catfish and eel respectively and were significantly different. 
These concentrations were consistently observed at 2 h after administration to carp and 
catfish. In eel however, the time to reach the highest drug concentration was between 
2 and 16 h after administration and was, due to this large variation, not significantly 
different from both other species. 
The declining part of the plasma flumequine versus time curve of the investigated 
species was characterized by a biphasic disposition profile which could be adequately 
described by the equation: 
Cp(t) = Ae'"' + Be?' 
where a is the distribution (first, faster disposition) slope, ß is the elimination (second, 
slower disposition) slope, A is the intercept of the mono-exponential distribution slope 
a with the ordinate, B is the intercept of the back-extrapolated mono-exponential 
elimination slope ß with the ordinate, and t is time. The observed individual plasma 
drug concentrations and the fitted disposition profiles of flumequine in carp, catfish and 
eel are depicted in Figure 2. 
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Figure 1. HPLC chromatograms of (A) standard solutions of flumequine (125 ngml ) and 7-hydroxy-
flumequine (50 ngml"'), (B) blank carp plasma extract and (C) extract of blank carp plasma spiked with 100 
ngml"1 7-hydroxy-flumequine and 250 ngml'1 flumequine. Peaks: 7-HFQ, 7-hydroxy-flumequine; FQ, 
flumequine. 
The respective mean distribution (t1/ia) and elimination (t1/ip) half-lives revealed 3.4 
h (interval used for fitting: 2-24 h) and 104.3 h (interval: 48-480 h) for carp; 7.3 h 
(interval: 8-24 h) and 59.5 h (interval: 48-192 h) for catfish; and 56.7 h (interval: 4-144 
h) and 451.2 h (interval: 192-1056 h) for eel. Mean values of selected pharmacokinetic 
parameters per species and the corresponding coefficients of variation are presented in 
Table 1. 
52 
Flumequine in plasma of carp, catfish and eel 
Cypnnus carpio 
8 0 0 
Ol 
C 
C 
O 
Ü 
c 
o 
o 
0) 
g 
er 
<ù 
E 
(0 
E 
co 
a 
Clarias gariepinus 
400 6 0 0 8 0 0 
8 0 0 
Time after peroral administration (h) 
Figure 2. Plasma flumequine concentrations in the individual animals and mean disposition profiles in 
common carp (Cyprinus carpio L., 1758), African catfish (Clarias gariepinus Burchell, 1822) 'and European 
eel (Anguilla anguilla L., 1758) following a single peroral administration of 18 mgkg"1 body weight. During 
the acclimation and experimental period fish were kept at 24 ± 1 °C and were deprived of feed. Different 
symbols represent data of different fish. The curves represent fits obtained by curve stripping using the 
intervals 2-24 and 48-480 h for carp; 8-24 and 48-192 h for catfish; and 4-144 and 192-1056 h for eel. 
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Table 1. Pharmacokinetic parameters of flumequine in common carp (Cyprinus carpio L., 1758), African 
catfish (Clarias gariepinus Burchell, 1822) and European eel (Anguilla anguilla L., 1758) (n=5 for each 
species) after a single peroral dose of 18 mg-kg"1 body weight 
Param 
A 
B 
a 
ß' 
t*a 
W 
AUC 
;ter 
(ng-mr') 
(ngml-1) 
(h"1) 
(h-1) 
(h) 
(h) 
(ng-h-ml"') 
Mean value and coefficient of variation 
Carp 
8221 (35.5) 
23 (31.3) 
0.2026 (7.2) 
0.0078 (56.2) 
3.4 (6.7) 
104.3 (36.6) 
38307 (34.7) 
Catfish 
1447 (43.3) 
44 (69.1) 
0.0961 (12.0) 
0.0127 (31.0) 
7.3 (11.5) 
59.5 (34.7) 
16746 (40.5) 
(%) 
Eel 
3095 (41.6) 
639 (36.7) 
0.0126 (21.1) 
0.0016 (22.0) 
56.7 (18.3) 
451.2 (29.5) 
545250 (31.1) 
Fish were kept at 24 ± 1°C and were not fed. 
Table 2. Statistical comparison of pharmacokinetic parameters of flumequine in common carp {Cyprinus 
carpio L., 1758), African catfish (Clarias gariepinus Burchell, 1822) and European eel (Anguilla anguilla L., 
1758) (n=5 for each species) after a single peroral dose of 18 mg-kg'' body weight 
Param 
A 
B 
a 
ß 
' * a 
*Kß 
AUC 
:ter 
(ng-mr1) 
(ng-mr') 
(h"') 
(h"1) 
0» 
(h) 
(ng-h-ml1) 
Carp 
vs 
catfish 
0.008 
NS 
0.008 
0.056 
0.008 
0.056 
0.032 
Two-tailed P-value 
Carp 
vs 
eel 
0.056 
0.008 
0.008 
0.008 
0.008 
0.008 
0.008 
Catfish 
vs 
eel 
0.033 
0.008 
0.008 
0.008 
0.008 
0.008 
0.002 
Fish were kept at 24 ± 1°C and were not fed. Significance of differences was tested with the two sample T-test 
in case of normality and otherwise by the non-parametric Wilcoxon rank sum test. NS, not significant 
(P>0.100). 
The statistical comparison of the pharmacokinetic parameters is summarized in 
Table 2. Significant interspecies differences were observed for most of the determined 
parameters. However, the most pronounced differences were generally found between 
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eel and the other two species. 
Only traces of 7-hydroxy-flumequine were found in any of the investigated species. 
The same held for glucuronide metabolites because no significant increase of the 
concentrations of flumequine and/or its 7-hydroxy metabolite were observed after 
deglucuronidation. 
Discussion 
The present study clearly demonstrates a species difference in the plasma disposition 
of flumequine after peroral administration. The 3 fish species were simultaneously 
exposed to identical external conditions, including an ambient temperature of 24°C. This 
temperature is within the range of the actually applied culture temperatures for the 
investigated species. Thus, it was possible to detect true species related differences and 
omit temperature influences with regard to drug disposition. However, at the temperature 
used, the relative metabolic rate will vary between the species. The observed 
pharmacokinetic differences might be less pronounced if the species were kept at their 
respective optimal temperatures for growth, indicating a more equal relative metabolic 
activity. 
The fish were deprived of feed to avoid increased intra- and interspecies variation 
in drug kinetics as a consequence of differences in nutritional status. Previous 
observations revealed that the inevitable manipulation of the animals caused a loss of 
appetite and eels proved to be particularly susceptible. As a consequence, a large 
variation in feed intake was observed between and within species (unpublished results). 
Therefore, the procedure of not feeding the animals was unavoidable to ensure valid 
cross species comparisons. 
The absorption of flumequine in the present study was rapid, so that not enough 
data were collected to characterize the absorption phase. The fast absorption might be 
explained by the administration of a dissolved drug without addition of any feed to 
fasting animals. 
The most important differences between the investigated species were observed in 
the distribution and elimination of the antibacterial agent. Species-dependent 
physiological dissimilarities in excretory organs, tissue composition and vascularisation 
and protein binding could cause these differences in pharmacokinetics (Ingebrigtsen, 
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1991). Metabolites other than the 7-hydroxy and glucuronide metabolites may be formed 
and can not be excluded as a possible explanation for the difference in elimination rate. 
Boon et al. (1991) found a slow biphasic disposition for flumequine following a 
single intramuscular administration of 9 mg-kg"1 body weight to eel. They attributed the 
long half-life of the first disposition phase partially to retarded absorption of the injected 
flumequine suspension. Absence of both, biotransformation and active excretion was 
suggested to explain the slow elimination. 
Under the present experimental conditions therapeutic plasma concentrations against 
Aeromonas hydrophila, with a minimum inhibitory concentration (MIC) of 75 ng-ml"1 
(Ledo et al, 1987), were maintained for about 1 day in both carp and catfish and more 
than 44 days in eel. The slow elimination of flumequine from eel indicates a prolonged 
withdrawal time for treated fish destined for human consumption (Van der Heijden et 
al, 1993). Moreover, it seems reasonable that lengthy exposure to the drug, might 
promote development of resistant bacteria (Bernoth, 1991) and eventual adverse side 
effects on the target animals health (Van der Heijden et al, 1992). 
Van Ginniken et al (1991) reported species-related differences between the 
pharmacokinetic profile of sulphadimidine in carp and rainbow trout acclimated at 10 
and 20°C. However, differences in mean body weight between the species in the latter 
study may have influenced the pharmacokinetic disparities. A possible effect of weight 
on pharmacokinetics within species, as demonstrated for some homeothermic animals 
(Lashev et al, 1992; Nouws et al, 1983), can also not be excluded with the 
experimental design of the present study. 
Assuming a positive correlation between the plasma concentration of a certain drug 
and its efficacy, an equivalent therapeutic effect of flumequine in carp, catfish and eel 
can only be achieved if the dose size and dosing interval are adapted accordingly. The 
same applies to the establishment of withdrawal periods. Prevention of unwanted drug 
residues in fish is only possible if withdrawal periods are formulated per species. Taking 
the influence of species, temperature and nature of the drug on pharmacokinetics in 
fresh water fish species into account, three-dimensional matrices for dose regimes and 
withdrawal times are needed to conceptualize the therapeutically correct use of drugs 
in the species concerned. 
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Abstract 
Tissue distribution and residue elimination of fiumequine, a quinolone derivative, 
was studied in European eel (Anguilla anguilla L., 1758) after a single intramuscular 
injection. Concentrations of fiumequine in muscle and liver were respectively similar 
and higher than in plasma during the investigated period (44 days). Elimination of 
fiumequine from the examined tissues was very slow and in the same order of 
magnitude as from plasma. After an observation period of more than 6 weeks the mean 
drug concentration in tissues and plasma was still above 85 ng-g"1 or -ml'1. 
Key-words: Fiumequine, Tissue residues, European eel. 
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Introduction 
At present, a growing importance of eel culture within the Dutch aquaculture 
industry can be observed. The majority of these fish is kept in recirculation systems with 
high stocking densities at temperatures between 20 and 25°C (Heinsbroek, 1988). These 
conditions are associated with a high prevalence of bacterial infections and ask for an 
active disease control. Accordingly, antibiotics such as Oxytetracycline and more recently 
flumequine, are administered on a large scale. 
However, in The Netherlands, compounds specifically licensed for use in 
aquaculture together with appropriate dosage regimes, withdrawal periods and 
monitoring programs for any residues are not available as yet. Nevertheless, according 
to EC requirements the prescribing veterinarian has to ensure that a withdrawal period 
of at least 500 degree-days (withdrawal period in days = 500 degree-days divided by 
temperature in °C) is observed, in case of extra-label use of drugs (Bernoth, 1992). 
Investigation of the pharmacokinetics of flumequine in eel plasma revealed that the 
disposition after intramuscular administration can be described by an open two-
compartment model with an elimination half-life of about 255 h (Boon et al, 1991). 
This indicates that the minimum withdrawal period stated by the EC might be too short 
to avoid unacceptable residues of flumequine in eels destined for human consumption. 
To provide more rational criteria for the use of flumequine in eel culture, the 
persistence of flumequine in eel plasma and several tissues was determined during a 44 
days period following a single intramuscular injection. 
Materials and Methods 
Twenty European eels (Anguilla anguilla L., 1758), with a mean weight of 469.6 
g (range 350.4-647.0), received an intramuscular injection with a commercially available 
flumequine suspension (Fluject®, Dopharma B.V., Raamsdonkveer, The Netherlands) at 
a dose of 9 mg-kg"1 body weight. The fish were randomly divided into four groups of 
5 animals. Each group was kept in a 150 1 aquarium with aerated tap water of ± 23°C. 
Fish were deprived of feed. 
At 48, 96, 192 and 1056 hours after injection one group of eels was sacrificed and 
plasma, bone, fat, posterior kidney, liver, muscle (non-injected region), skin and spleen 
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were sampled. Plasma and tissue samples were deep frozen at -20°C pending analysis 
of the drug concentration. 
Furthermore, the longest-lived group was used to determine the concentration vs 
time profile in plasma by taking 17 blood samples of 0.5 ml from each animal during 
the time course of the experiment. The results of this part of the study have already been 
published (Boon et al, 1991). 
After thawing, the tissues were blendered and diluted 1:5 (w/v) with phosphate 
buffer (pH 7.4). Subsequently, an extraction procedure with dichloromethane was 
performed, the extract was evaporated and the dry matter was dissolved in eluent (125 
ml acetonitrile, 200 ml dimethylformamide and 675 ml distilled water containing 3 g 
phosphoric acid and 1 g tetramethylammonium chloride). Thereafter, the samples were 
analyzed by means of high performance liquid chromatography (HPLC) using 
fluorescence detection (Boon et al, 1991). With the proposed procedure it was possible 
to detect flumequine as well as its 7-hydroxy metabolite. The mean recovery of the 
parent compound for the measured range was >80% in plasma. In tissues it varied 
between 69.2% in skin to 87.8% in muscle. The limit of detection in plasma and tissues 
was 2 ngml"1 and 10 ng-g"1 respectively. Measured flumequine concentrations were 
corrected for the recovery in the corresponding tissue. 
Results 
The concentrations of flumequine in tissues and plasma of European eel after a 
single intramuscular injection are shown in Figure 1. The time to reach maximum 
concentrations of flumequine ( t ^ J in tissues (48-192 h) was comparable to t , ^ in 
plasma (96 h). Remarkably, t,,,^ in bone and skin was achieved in about the same time 
as in plasma. Mean maximum concentrations in tissues ranged from 725 ng-g"1 in bone 
to 12100 ng-g"1 in fat. At the end of the observation period (t=1056 h) the mean drug 
concentrations in the investigated tissues and plasma were still clearly above the 
detection limit of the applied HPLC method; in decreasing order: liver (769 ng-g"1) > 
fat (427 ng-g"1) > muscle (238 ng-g"1) > plasma (213 ng-ml'1) > spleen (197 ng-g"1 > 
skin (153 ng-g"1) > bone (89 ng-g"1) > kidney (85 ng-g"1). 
Elimination of flumequine from tissues was in the same order of magnitude as from 
plasma. However, from bone and skin the elimination was slower. 
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Figure 1. Scatter diagrams of flumequine concentrations in tissues of European eel (Anguilla anguilla L., 
1758) following a single intramuscular injection of 9 mg-kg"1 body weight. Fish were kept at ± 23°C. The 
lines connect the means at the different sample times. 
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Ratios of tissue levels to the plasma level of flumequine are given in Table 1 in 
order to quantify the affinity of the drug for particular tissues of eel. Forty-eight hours 
p.i. the highest flumequine concentration was found in plasma. From that time onwards, 
flumequine concentrations in liver and fat, if determined, were higher than in plasma. 
The mean muscle/plasma concentration ratio was 1.01 +0.10. Statistical analyses 
revealed a significant correlation (r=0.993; P<0.05) between both flumequine 
concentrations. 
No 7-hydroxy-flumequine was observed in any of the analyzed samples. 
Table 1. Ratios of mean tissue levels divided by the mean plasma level of flumequine in European eel 
(Anguilla anguilla L., 1758) after a single intramuscular injection at a dose of 9 mgkg"1 body weight 
Time 
(h) 
48 
96 
192 
1056 
Bone 
0.11 
0.08 
0.09 
0.42 
Fat 
ND 
ND 
3.20 
2.00 
Kidney 
0.19 
0.26 
0.46 
0.40 
Tissue 
Liver 
0.81 
1.04 
2.54 
3.61 
Muscle 
0.99 
1.08 
0.85 
1.12 
Skin 
0.14 
0.13 
0.09 
0.72 
Spleen 
0.35 
0.50 
1.39 
0.92 
Fish were kept at ± 23°C. ND, not determined. 
Discussion 
The minimum inhibitory concentrations (MICs) of flumequine for most important 
eel pathogenic bacteria range from <0.08 to 0.3 ngml"1 (Ledo et al, 1987). 
Concentrations of flumequine in plasma and in most of the tissues of European eel after 
intramuscular injection are higher than these MIC values for more than 44 days. This 
may explain the effective treatment of bacterial infections in eel after single dose 
administration of flumequine. Moreover, dose reduction without loss of effectiveness 
seems feasible. However, the long drug persistence in plasma and tissues may lead to 
undesirable residues of flumequine if a withdrawal period of 500 degree days (i.e. 22 
days), which is in accordance with the EC directive, is applied. To evaluate the possible 
hazards for public health, maximum residue levels as well as properly designed dosage 
regimen studies and monitoring programs are needed. 
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Boon et al. (1991) mentioned the absence of biotransformation and active excretion 
as possible causes of the slow elimination from plasma. From the present results it is 
concluded that good tissue distribution and slow release from tissues, especially bone 
and skin, may also contribute to the slow elimination from plasma. 
Because of the significant correlation between the drug concentration in muscle and 
plasma, the plasma flumequine concentration may provide a useful, simple tool for 
estimating residues in muscle of eel, which is the most important tissue with respect to 
human consumption. 
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Abstract 
Monoclonal antibodies (mAbs) to European eel (Anguilla anguilla L., 1758) 
immunoglobulin (Ig) were produced, characterized and tested for applicability in a 
number of immuno(cyto)chemical assays. The selected mAbs, WEI 1 and WEI 2, were 
specifically reactive with Ig heavy and light chain, respectively. WEI 1 appeared to react 
with all or nearly all Ig molecules, B cells and plasma cells. WEI 2 was reactive with 
a subpopulation of those cells, indicating that European eel possesses at least two 
antigenically different light chain types. Both mAbs could be used for detection of 
antigen-specific antibodies in plasma by means of an enzyme-linked immunosorbent 
assay (ELISA). 
Key-words: Monoclonal antibodies, European eel, Immunoglobulin, B cells, ELISA. 
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Introduction 
The growth of the aquacultural sector and the involved trade in living fish, 
increasingly asks for assessment of the health status of these animals. For this purpose 
definition of fish health parameters is required. At present, different parameters have 
been described, including those associated with behaviour, physiology and performance 
(Schreck, 1990), but more readily determinable haematological (Blaxhall, 1972) and 
immunological parameters (Anderson, 1990) are needed. 
Immunological parameters, such as total and specific plasma immunoglobulin (Ig) 
levels and the number of B and plasma cells in different tissues, may be used to 
evaluate immunocompetence and associated disease resistance. Monoclonal antibodies 
(mAbs) specifically reacting with Ig provide a useful tool for proper determination of 
these immunological parameters. 
During the last decade, mAbs have been produced to Ig of a number of teleost 
species (Lobb and Clem, 1982; Deluca et al, 1983; Secombes et al, 1983; Thuvander 
et al, 1990; Sanchez et al, 1993; Navarro et al, 1993). This has greatly contributed to 
an improved understanding of the architecture and functioning of the immune system 
of teleost fish in general and the corresponding species in particular. 
Unfortunately, mAbs to European eel (Anguilla anguilla L., 1758) Ig were not yet 
available, despite the growing economical importance of this predominantly intensively 
cultured species (Heinsbroek, 1991). The present study describes the production, 
characterization and applicability of mAbs specific to Ig of European eel using a number 
of immuno(cyto)chemical assays. 
Materials and methods 
Fish 
Non-sexed European eels (Anguilla anguilla L., 1758), weighing 80 to 180 g, were 
either obtained from a local commercial farm or raised, from the glass eel stage 
onwards, at the Wageningen Agricultural University. Fish were maintained in aquaria 
with recirculating, aerated and filtered water of 24 ± 1°C. The diet consisted of pelleted 
eel feed (Provimi B.V„ Rotterdam, The Netherlands). Blood was sampled from the 
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caudal, subvertebral vessels with a heparinized syringe, after fish were sedated in water 
containing Hypnodil® (Janssen Pharmaceutica B.V., Beerse, Belgium; 0.3 mlT1). 
Purification of plasma Ig 
Plasma samples of 25 eels were pooled and 10% (v/v) 1 M CaCl2-2H20 and 2% 
dextran sulphate 500 were added. After stirring 30 min on ice and centrifuging for 40 
min at 10,000xg, the supernatant was precipitated twice during 4 h with saturated 
(NH4)2S04. Subsequently, the precipitate was dissolved in 0.01 M Tris buffer (pH 8.0) 
and loaded on a gel filtration column (Sephacryl® S-500; Pharmacia, Uppsala, Sweden). 
For selection, the collected Ig-containing fractions were subjected to sodium dodecyl 
sulphate Polyacrylamide gel electrophoresis (SDS-PAGE) under reducing conditions 
(Laemmli, 1970). Fractions with adequate purity were pooled and stored at -20°C. 
Preparation of mAbs 
A Balb/c mouse was injected intraperitoneally (i.p.) with 60 |^ g eel Ig in Freund's 
complete adjuvant (1:1; DIFCO, Detroit, MI, USA), 9 weeks later followed by i.p. 
injection of 100 (ig eel Ig without adjuvant. Three days later the spleen was extirpated 
and a single cell suspension was prepared. Fusion of splenocytes with the mouse 
myeloma cell line Sp2/0-Ag-14 and subsequent culture and selection of hybridomas was 
performed according to the method described by Schots et al. (1992). Hybridomas were 
screened by enzyme-linked immunosorbent assay (ELISA) for production of anti-eel Ig 
antibodies of the IgG class. Briefly, microtiter plates coated with eel Ig were incubated 
with hybridoma culture supernatant and stained with alkaline phosphatase conjugated 
goat anti-mouse IgG (GAM IgG-AP; 1:5000; Sigma Chemical Co., St. Louis, MO, 
USA). Positive hybridomas were subjected to further selection using indirect 
immunofluorescence reaction on fixed cytocentrifuge slides of pronephros and spleen 
cells and flow cytometric analysis of isolated peripheral blood leucocytes (PBL) labelled 
by indirect immunofluorescence. The selected hybridomas were recloned and tested 
again by means of the procedures described above. The IgG isotype of selected mAbs 
was estimated by means of a sandwich ELISA, using rat anti-mouse Ig typing sera 
coated microtiter plates (Schots et al, 1992). 
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Immunochemistiy 
Western blotting 
SDS-PAGE of eel Ig and whole plasma was carried out using 4% gels or 7.5-15% 
gradient gels for separating native and 2-mercaptoethanol denaturated proteins, 
respectively. For estimation of molecular weights, prestained standards (Bio-Rad, 
Richmond, CA, USA) were used. After electrophoretic transfer of proteins onto 
nitrocellulose, transfers were soaked for 1 h in 0.02 M Tris/0.05 M NaCl (pH 7.4; TBS) 
containing 1% (w/v) BSA to block non-specific binding sites, washed in TBS containing 
0.05% (v/v) Tween 20 (TTBS) and cut into strips. The latter were successively 
incubated for 1 h with 1:10 diluted anti-eel Ig mAbs and GAM-AP (1:3000; Bio-Rad, 
Richmond, CA, USA). Next, the strips were put in 100 mM Tris-HCl buffer (pH 9.5) 
containing 100 mM NaCl and 5 mM MgCl2 and subsequently stained with nitro blue 
tetrazolium and 5-bromo-4-chloro-3-indolyl phosphate solution. 
Affinity chromatography 
Anti-eel Ig affinity column was prepared by loading a column, packed with protein 
G-Sepharose® beads (Pharmacia, Uppsala, Sweden), with an anti-eel Ig mAb. Unbound 
material was removed by successively washing with TBS (pH 7.2), TBS (pH 4.5) and 
TBS/2 M NaCl (pH 8.0). Thereafter, purified eel Ig was applied onto the column and 
subsequently eluted with TBS (pH 4.5). From the application of anti-eel Ig mAb 
onwards, the flow through was evaluated for protein content by UV-absorbence at 280 
nm and collected as 300 ul fractions. Thereafter, 100 \i\ of these fractions was analyzed 
for the presence of eel Ig by means of a dot blot assay, as described by Navarro et al. 
(1993). 
Immunocytochemistry 
Cytocentrifuge slides 
Eel was exsanguinated and pronephros and spleen were extirpated. Thereafter, cell 
suspensions were prepared in 65% RPMI-1640 (Gibco, Breda, The Netherlands) 
containing 10 IU-mF1 heparin, 0.1% (w/v) NaN3 and 1% (w/v) BSA (eRPMI; pH 7.4, 
240 mOsmkg"1), by squeezing the tissues through a nylon gauze filter. Preparation and 
subsequent indirect immunofluorescence labelling of cytocentrifuge slides was carried 
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out as previously described by Navarro et al. (1993). Additional staining was performed 
by successively incubating the slides with two different anti-eel Ig mAbs (1:100), 
alternated with either tetramethyl rhodamine isothiocyanate or fluorescein isothiocyanate 
conjugated rabbit anti-mouse Ig antibodies (RAM-TRITC or RAM-FITC; 1:50; 
Dakopatts, Glostrup, Denmark). Slides were examined using a fluorescence microscope 
with phase-contrast equipment (Nikon, Microphot FXA). 
Flow cytometry 
Leucocytes with densities between 1.020 and 1.070 g-cm"3 were isolated from 
peripheral blood, pronephros and spleen cell suspensions on a discontinuous Percoll® 
(Pharmacia, Uppsala, Sweden) density gradient. Cells (0.5x106) were washed, 
resuspended in 250 u.1 of different dilutions of anti-eel Ig mAbs and incubated for 30 
min at 0°C. Subsequently, cells were washed, and incubated for 30 min at 0°C with 
RAM-FITC (1:100; Dakopatts, Glostrup, Denmark). Cell suspensions were analyzed 
with a FACStar® flow cytometer (Becton Dickinson, Mountain View, CA, USA) 
equipped with a 5 W argon laser, tuned at 488 nm. 
Immuno-electron microscopy 
Eel PBL with densities between 1.020 and 1.070 g-cm"3 were isolated as described 
above. After washing, 4xl06 cells were resuspended in 1 ml 1:100 diluted anti-eel Ig 
mAb, incubated for 45 min at 0°C, washed again, and incubated for another 45 min at 
0°C with 100 ul goat anti-mouse Ig coupled to 15 nm gold particles (GAM-G15; 1:5; 
E-Y Labs inc., San Mateo, CA, USA). Cell pellets were prepared for electron 
microscopy as described by Van Diepen et al. (1991). 
ELISA for detection of specific antibodies 
Seven eels were immunized intramuscularly (i.m.) with 10 \xg DNP494KLH 
(Calbiochem, La Jolla, CA, USA) in 50 ul phosphate buffered saline (PBS; pH 7.2), 
mixed with an equal volume Freund's incomplete adjuvant (DIFCO, Detroit, MI, USA). 
Simultaneously, 3 control eels received an i.m. injection with 100 ju.1 PBS (pH 7.2). 
After 21 days control fish and three immunized fish were bled, plasma was obtained and 
stored at -20°C until detection of specific antibodies. At day 36 and 48, respectively, the 
remaining 4 fish were boosted and sampled according to the procedures described for 
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the priming injection. Antibodies to DNP-KLH or DNP alone were detected by means 
of an ELISA, essentially the same as described by Arkoosh and Kaattari (1990). Major 
modifications were the use of DNP494KLH-coated plates next to DNP44BSA-coated 
plates. Furthermore, 5% (w/v) lean milk powder in TTBS was used for blocking non-
specific binding sites. 
Results 
Production and selection of mAbs 
After the fusion, more than 30% of the 200 harvested clones produced antibodies 
of the IgG class, reacting with purified eel Ig. Additional screening of these clones by 
means of indirect immunofluorescence reactions on cytocentrifuge slides and flow 
cytometry, resulted in 30 positive clones, of which 15 were still positive after recloning 
and subsequent testing. Western blots of purified eel Ig, run under reducing conditions, 
yielded only 3 promising mAbs, one of them immunoreactive with the Ig heavy (H) 
chain, and the other 2 immunoreactive with the Ig light (L) chain. Because the latter 2 
mAbs appeared to recognize the same population of lymphocytes, only 2 clones (WEI 
1 and WEI 2) were selected for further use. 
Characterization of mabs 
Immunochemistry 
Figure 1 shows the immunoreaction of WEI 1 and WEI 2 in Western blots of non-
reduced and reduced purified Ig and reduced whole plasma. Eel Ig appeared to occur 
in a tetrameric, dimeric and monomeric form, which were all reactive with both mabs. 
Apart from that, WEI 1 and WEI 2 showed a specific reaction with the Ig H (± 70 kDa) 
and L chain (± 25 kDa), respectively. 
Isotyping revealed that WEI 1 belongs to the IgG, subclass whereas WEI 2 was 
found to be of the IgG2a subclass. 
Affinity chromatography of purified eel Ig, by means of Sepharose® immobilized 
WEI 1, and subsequent analysis of the flow through by a dot blot assay using WEI 2, 
revealed no demonstrable Ig in fractions collected before saturation of the column. 
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Figure 1. Western blots comparing the reactions of the anti-ee! Ig mAbs. Lane A, amido black stained 
molecular weight markers with their respective molecular weights (kDa); Lane B, amido black stained sample; 
Lane C, immuno-stained with WEI 1; Lane D, immuno-stained with WEI 2. (a) Non-reduced Ig sample; (b) 
Reduced Ig sample; (c) Reduced whole plasma sample. T, tetramer; D, dimer; M, monomer; H, heavy chain; 
L, light chain. 
Immunocytochemistry 
Both anti-eel Ig mAbs showed specific immunoreaction in cytocentrifuge slides of 
pronephros and spleen cells. Surface labelling of a subset of the lymphocytes was 
observed, as well as strongly stained cytoplasm of plasma cells. Additional staining of 
pronephros cells with WEI 1 followed by WEI 2 and vice versa showed that WEI 2 
reacted with a smaller number of cells than WEI 1 (Figure 2). 
Table 1 summarizes mean percentages of Ig-bearing (slg+) cells in peripheral blood, 
pronephros and spleen cell suspensions, as measured by flow cytometry after labelling 
with WEI 1 or WEI 2. All 3 suspensions revealed around 25% slg+ cells with WEI 1, 
but much lower percentages (9.1-16.2%) with WEI 2. Figure 3 shows the forward/side 
(90°) scatter (FSC/SSC) dot plot of PBL and corresponding fluorescence histograms of 
a representative fish. Simultaneous incubation of PBL suspensions with equal volumes 
of WEI 1 and WEI 2 revealed no significant increase (one-tailed two sample T-test, 
P=0.15) of slg+ cells compared to suspensions labelled only with WEI 1. 
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Pre-embedding immunogold labelling of PBL with either WEI 1 or WEI 2 resulted 
in selective surface labelling of a subset of the lymphocytes. The gold particles were 
mainly found in clusters, although labelling intensity per cell was apparently higher after 
using WEI 2 compared to WEI 1 (Figures 4a and 4b). 
Figure 2. Fluorescence micrographs of a cytocentrifuge preparation of spleen cells immuno-stained with 
WEI 2 and RAM-FITC followed by WEI 1 and RAM-TRITC. Scale bar = 20 urn. (a) WEI 2-immunoreactive 
cells photographed with a FITC filter combination, (b) WEI 1 and WEI 2-immunoreactive cells in the same 
slide, photographed with a TRITC filter combination. 
Table 1. Mean percentages (± SD) of Ig-bearing (slg+) cells labelled by indirect immunofluorescence with 
WEI 1 or WEI 2 in peripheral blood, pronephros and spleen cell suspensions 
mAb 
WEI 1 
WEI 2 
blood (n=13) 
26.0 ± 6.2 
16.2 ± 4.4 
slg+ cells (%)* 
pronephros (n=3) 
24.0 + 8.6 
9.1 ± 2.7 
spleen (n=3) 
25.3 ±11.7 
13.1 + 7.0 
* Determined using gated, lymphoid cells as shown in Figure 3a. 
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Figure 3. Flow cytometry generated forward/side (90°) scatter (FSC/SSC) profile and fluorescence 
histograms of PBL labelled by indirect immunofluorescence with WEI 1 and/or WEI 2. (a) FSC/SSC dot plot 
of PBL with gated, lymphoid cells; (b) Combined (smoothed) FITC fluorescence histogram of gated, lymphoid 
cells stained with WEI 1 ( ), WEI 2 (• • • •) or with WEI 1 + WEI 2 ( ). 
ELISA for detection of specific antibodies 
WEI 1 or WEI 2 gave similar results when applied in an ELISA for detection of 
DNP (Figures 5a and 5b) or DNP-KLH-specific (Figures 5c and 5d) antibodies in 
plasma of immunized eels. Especially in case of anti-DNP-KLH detection, low 
background values were recorded for plasma from sham-immunized fish. Animals 
immunized twice exhibited much higher mean titers than those immunized once. 
Discussion 
The mAbs produced and described in the present study were extensively selected 
to ensure an adequate, specific reaction in a broad range of immuno(cyto)chemical 
assays. Only mAbs of the IgG class were selected to avoid problems with clumping of 
cells during reactions on cell suspensions, as reported for antibodies of the IgM class 
by Van Diepen et al. (1991). The specificity of the selected mAbs is most clearly 
illustrated by the Western blots of whole plasma and the immunogold labelling of PBL. 
In both cases a very specific reaction was observed, while they were exposed to a great 
range of different antigenic determinants. 
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Figure 5. Mean DNP-KLH and DNP antibody titration curves after sham-immunization (—o—; n=3), 
priming (—v—; n=3) and boosting (—A—; n=4). Bars represent SE. (a) DNP antibody detection using WEI 1 
as secondary antibody and DNP-BSA as coating, (b) DNP antibody detection using WEI 2 as secondary 
antibody and DNP-BSA as coating, (c) DNP-KLH antibody detection using WEI 1 as secondary antibody and 
DNP-KLH as coating, (d) DNP-KLH antibody detection using WEI 2 as secondary antibody and DNP-KLH 
as coating. 
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Three forms of Ig, namely monomers of about 190 kDa, dimers of about 360 kDa 
and tetramers of about 760 kDa, were found in plasma of eel. All three forms are also 
described for serum and mucus Ig of common carp (Rombout et al., 1993). However, 
in serum of gilthead seabream merely monomeric and tetrameric Ig were found (Navarro 
et al., 1993). On the other hand, Lobb (1986) described dissociation of channel catfish 
tetrameric Ig into all possible combinations of covalently linked H-L chain units. 
Combining the present results with those of the authors cited, variation in structural 
characteristics between Ig of different teleost species appears to exist. 
Ig of fish has long been thought to be composed of respective uniform H and L 
chains. This general concept has been abandoned because evidence for diversity of Ig 
in a number of teleost species has become available. Differences in molecular weights 
and/or antigenic determinants of H and L chains, have been described for some teleost 
fish (Lobb and Clem, 1981; Lobb et al., 1984; Sanchez et al, 1989; Koumans-van 
Diepen, 1993; Rombout et al., 1993). The present work revealed neither indications for 
molecular weight differences in H and L chains, nor for the existence of antigenically 
different H chains. However, indirect evidence was achieved for antigenic differences 
within L chains. Flow cytometry showed that only about 60% of the WEI 1 (anti-H 
chain) reactive PBL were immunoreactive with WEI 2 (anti-L chain). This indicates that 
at least 2 antigenically different L chain types exist in eel. Differences in L chains have 
previously been described for channel catfish (Lobb et al, 1984) and rainbow trout 
(Sanchez and Dominguez, 1991; Sanchez et al, 1993). 
Affinity chromatography of eel Ig, using immobilized WEI 1, revealed no detectable 
WEI 2-immunoreactive Ig in the fractions collected before saturation of the column. 
Assuming random distribution of the different L chains and considering the high 
sensitivity of the dot blot assay used for Ig-detection, WEI 1 seems to react with all or 
at least nearly all Ig. 
The percentage of WEI 1-immunoreactive PBL (± 26%) appeared to be low, 
compared to ± 45% in rainbow trout (Thuvander et al, 1990), ± 37% in channel catfish 
(Ainsworth et al, 1990) and ± 48% in adult common carp (Koumans-van Diepen et al, 
1994). This discrepancy may be explained by a dilution effect of thrombocytes. About 
10-60% of these cells were observed after differential leucocyte counts in cytocentrifuge 
preparations of the lymphocyte-enriched fraction used for determination of the relative 
amount of slg+ cells (unpublished results). The cell population used for flow cytometric 
analyses was gated on the basis of FSC/SSC characteristics and will consist of both 
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lymphocytes and thrombocytes, as size and shape of these cell types are often nearly 
identical (Kusuda and Ikeda, 1987). Similarity in FSC/SSC profile of lymphocytes and 
thrombocytes was previously reported by Koumans-van Diepen (1993) for common 
carp. 
The respective proportions of slg+ lymphocytes, as determined with WEI 1, in 
pronephros and spleen were about 24 and 25%. These percentages are comparable with 
those reported for the corresponding organs in several other fish species, such as 
gilthead seabream (Navarro et al, 1993), channel catfish (Ainsworth et al, 1990), 
rainbow trout (DeLuca et al, 1983; Thuvander et al, 1990) and common carp 
(Koumans-van Diepen et al, 1994). 
Application of WEI 1 and WEI 2 in immuno-electron microscopy on isolated PBL 
confirmed that both mAbs actually showed a specific reaction with a part of the 
lymphocyte population. In accordance with the observations of Van Diepen et al. (1991) 
and Navarro et al. (1993) the gold particles occurred more or less clustered at the 
surface of the lymphocytes, suggesting that this might be a common feature for the 
distribution of Ig molecules on fish B cells. 
Labelling intensity was consistently higher with WEI 2 than with WEI 1, in both 
the immunogold and immunofluorescence labelling. However, differences in staining 
intensity of both mAbs on fixed cells, Western blots and in the ELISA were not 
observed. Consequently, differences in the reactivity of the mAbs have to be attributed 
to the attainability of the recognized determinants on living cells rather than to 
differences in their affinity for Ig. 
Both mAbs appeared to be suitable for the detection of anti-DNP or anti-DNP-KLH 
antibodies by means of an ELISA, because clear differences were not found in the 
titration curves after using either WEI 1 or WEI 2 as secondary antibody. The higher 
anti-DNP background titres found, may be dedicated to the presence of anti-BSA 
antibodies or antibodies cross-reacting with BSA. As a consequence, lean milk powder 
was used as a blocking protein, because the use of BSA caused very high background 
staining (not shown). In any case, clear differences were not found between the anti-
DNP and anti-DNP-KLH titration curves, suggesting that eel predominantly reacts 
against the hapten (DNP). 
In conclusion, WEI 1 and WEI 2 proved to be useful in a variety of immunoassays. 
They might be employed for studies on European eel health, like monitoring (functional) 
characteristics of the immune system and epizootic studies. 
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Abstract 
The influence of flumequine on mitogen induced lymphoid cell proliferation in 
European eels (Anguilla anguilla L., 1758) was studied. For this purpose an in vivo test, 
using peroral drug administration followed by successive intraperitoneal injections with 
concanavalin A (Con A) or bacterial lipopolysaccharide (LPS) and 5-bromo-2'-
deoxyuridine, was applied. Direct counting of proliferated cells in blood smears revealed 
that flumequine possesses mitogenic properties. A synergistic and an antagonistic effect 
of the drug was observed after LPS and Con A stimulation, respectively. Flow 
cytometric analysis of peripheral blood lymphoid cells showed a significant reduction 
of the mean proportion surface immunoglobulin positive cells in the flumequine-treated 
animals. It is concluded that flumequine enhances proliferation of lymphoid cells 
(probably surface immunoglobulin negative cells) in eel under the present experimental 
conditions. 
Key-words: European eel, Flumequine, Lymphocyte stimulation, Immunomodulation. 
84 
Influence of flumequine on mitogen responses in eel 
Introduction 
Culture of European eel {Anguilla anguilla L., 1758) is characterized by high 
stocking densities of fish originating from wild populations. These fish are not selected 
to cope with intensive culture conditions, associated with high infection pressure from 
the environment and decreased resistance of the animals caused by crowding stress. 
These circumstances often precede infectious diseases followed by morbidity and 
mortality which in turn may cause high production losses. It is attempted to reduce this 
damage by (1) zootechnical and hygienic measures and (2), in case of failure of these 
measures, by administration of drugs. Vaccination, which is gaining importance in 
disease prevention of several cultured fish species, is not yet reported for eel culture. 
At Dutch eel farms, flumequine is one of the main drugs for bacterial disease 
control. It is used prophylactically at times of stressful farm operations, e.g. the 
recurring weighing and sorting, and curatively after disease outbreaks. In this respect, 
the very slow elimination of flumequine in eel may be of concern (Boon et al, 1991; 
Van der Heijden et al, 1994). Several hazards have been mentioned for excessive use 
of drugs, like development of resistant pathogens, unacceptable residues in marketable 
consumption fish, pollution of the environment and last but not least (undesired) side 
effects on fish health (Van der Heijden et al, 1992). 
Some drugs have shown to interfere with immunological processes in fish (Grondel 
et al, 1985; Dunier et al, 1991; Siwicki et al, 1994). Immunostimulating effects 
provide possibilities for boosting protective abilities of fish. For instance the 
anthelmintic levamisole appeared to elevate nonspecific and specific defence 
mechanisms, resulting in increased protection against disease in vaccination trials 
(Anderson and Jeney, 1992). Immunosuppression as for example described for 
Oxytetracycline in carp (Rijkers et al, 1980; Rijkers et al, 1981; Grondel and Boesten, 
1982; Grondel et al, 1985), must be prevented because a properly functioning immune 
system is essential for the final elimination of a pathogen. Moreover, an impaired 
defence system means an increased susceptibility to (superinfections. 
In the initiation of cellular and humoral responses proliferation of B- and T-
lymphocytes plays an important role in mammals (Roitt et al, 1993) but also in fish 
(Koumans-van Diepen et al. 1994). The extent of lymphocyte proliferation after 
antigenic or mitogenic stimulation may be used as a parameter to assess 
immunocompetence (Anderson, 1990). In the present study the effect of flumequine on 
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the proliferative capacity of lymphoid cells in European eel was evaluated after in vivo 
stimulation with a presumed B cell or T cell mitogen and subsequent determination of 
proliferated lymphoid cells in peripheral blood. 
Materials and methods 
Fish 
Eighty non-sexed European eels (Anguilla anguilla L., 1758) with a mean weight 
(± SD) of 98.2 + 20.9 g were obtained from a local commercial farm where the fish 
were raised without using any antibacterial drugs by request. Two weeks before the start 
of the experiment feeding was ceased and the fish were randomly assigned to eight 
groups of ten animals. Each group was allocated to a 70-litre aquarium with aerated, 
running tap water at a mean temperature (± SD) of 23 ± 0.5°C. 
Experimental design 
A schedule of the successive treatments per group is presented in Table 1. 
Manipulations of the animals were performed after sedation in water containing 300 
ppm Hypnodil® (Janssen Pharmaceutica B.V., Beerse, Belgium). 
Table 1. Schedule of the experimental design 
Time 
(days) 
0 
1 
6 
7 
1 
Con A 
BrdU 
2 3 
Flumequine 
LPS PBS 
BrdU BrdU 
Treatment 
4 . 
*PBS 
PBS 
Blood 
group 
5 
Con A 
BrdU 
sampling 
6 7 
No medication 
LPS PBS 
BrdU BrdU 
S 
*PBS 
PBS 
Blood sampling for drug determination. 
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Drug administration 
Non-medicated and medicated feed slurries were freshly prepared. The former consisted 
merely of ground eel feed (Provimi B.V., Rotterdam, The Netherlands) and an equal 
volume of distilled water whereas the latter contained also 4 mg-ml"1 flumequine 
(Flumiquil®, Pitman-Moore, Haarlem, The Netherlands). Each fish received 5 mlkg"1 
body weight (BW) of the allotted feed slurry by intubation of the stomach. This 
corresponds to a single administration of a generally used flumequine dose of 20 mg-kg" 
1
 BW. 
Mitogen and BrdU administration 
The mitogens, concanavalin A (Con A) and lipopolysaccharide from Salmonella 
typhimurium (LPS), and the thymidine analogue 5-bromo-2'-deoxyuridine (BrdU) were 
purchased from Sigma Chemical Company (St. Louis, MO, USA). Mitogen and BrdU 
solutions with respective concentrations of 1 and 12.5 mg-ml"1 were prepared in 
phosphate buffered saline (PBS; pH 7.2). Eels were intraperitoneally (i.p.) injected with 
Con A or LPS at a dose of 2.5 mg-kg"1 BW. At the same time, the control groups were 
sham treated with an equivalent volume of the solvent (PBS). One day prior to 
sampling, BrdU (250 mg-kg"1 BW) or an equivalent volume of PBS (controls) was i.p. 
injected. 
Sampling 
Heparinized blood samples of 0.5 ml were collected from the caudal vein. Blood smears 
were prepared and stored in the dark. The remaining blood was processed for flow 
cytometric determination of relative numbers of surface immunoglobulin positive (slg+) 
lymphoid cells. 
To confirm the presence (or absence) of the drug, 0.5 ml blood of the animals in 
group 4 and 8 was sampled just prior to the first PBS injection (cf. Table 1). Plasma 
was obtained and stored at -20°C until analysis. 
Immunocytochemistry 
Blood smears 
Air dried blood smears were fixed in methanol containing 0.03% H202 for 10 min on 
ice. After DNA-denaturation in 2 N HCl for 25 min at room temperature, slides were 
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rinsed twice in 0.05 M Tris/HCl (pH 7.6; TBS). Non-specific binding sites were blocked 
with 10% fetal calf serum in TBS (v/v). Subsequently, slides were successively 
incubated with a monoclonal anti-BrdU antibody (Eurodiagnostics B.V., Apeldoorn, The 
Netherlands) and with horseradish peroxidase conjugated goat anti-mouse 
immunoglobulin (GAM-HRP; BioRad, Richmond, CA, USA). After each incubation step 
the slides were rinsed 4 times for 3 min in TBS. HRP was demonstrated by a 10 min 
incubation with 0.1% (w/v) 3,3'-diaminobenzidine (Sigma Chemical Company, St. 
Louis, MO, USA) in TBS. Smears were rinsed, counterstained with Giemsa, dehydrated 
and embedded in DePeX (BDH, Dorset, UK). 
Per smear the percentage of proliferated (BrdU+) lymphoid cells was calculated after 
direct counting of 200 lymphoid cells. Five randomly chosen smears of each group were 
analyzed accordingly. 
Flow cytometry 
Heparinized peripheral blood samples were diluted 1:1 with 65% RPMI-1640 (Gibco, 
Breda, The Netherlands) containing 10 IUml"1 heparin, 0.1% (w/v) NaN3 and 1% (w/v) 
BSA (eRPMI; pH 7.4, 240 mOsmkg"1). A lymphocyte enriched fraction was obtained 
by separating the cells over a discontinuous Percoll® (Pharmacia, Uppsala, Sweden) 
density gradient (1.020 and 1.070 gem"3) and collecting the interphase. After washing 
twice in eRPMI, the cells were incubated for 30 min at 0°C with mouse monoclonal 
antibody (WEI 1), specifically reacting with the heavy chain of plasma and membrane 
bound eel immunoglobulin (Van der Heijden et al, 1995). Thereafter, the cells were 
washed twice and incubated for another 30 min at 0°C with rabbit anti-mouse 
immunoglobulin conjugated to fluorescein isothiocyanaat (RAM-FITC; Dakopatts, 
Glostrup, Denmark). After washing, cells were analyzed with a FACStar® flow 
cytometer (Becton Dickinson, Mountain View, CA, USA) and the Consort 30 data 
analysis package. In each sample 10 000 cells were counted and only cells complying 
with morphological characteristics of lymphoid cells were used to determine the relative 
number of slg+ lymphoid cells. 
Determination offlumequine 
Plasma samples were pooled per group and drug concentrations were determined 
using high performance liquid chromatography (Van der Heijden et al, 1994). 
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Statistical analysis 
Data were checked for normality and outliers by means of Wilk-Shapiro/rankit plots 
and box plots, respectively. Relative numbers of both BrdU+ and slg+ cells after 
different treatments were examined by means of two-tailed two sample T-tests. If 
differences between group means were small compared with variances within groups, 
two-way analysis of variance (ANOVA) was used. In the latter case, subsequent 
pairwise comparisons of means were performed using the least significant difference 
method (LSD T-test). All testing was performed with the computer program 
STATISTIX (1985) at a significance probability level of 5%. 
Results 
The mean plasma flumequine level ât 24 h after administration was 5.5 ugml"1, 
whereas the drug was absent in the sample of non-medicated animals. The proportions 
of both BrdU+ and slg+ lymphoid cells were normally distributed and no outliers were 
detected. 
Figure 1. Micrograph of a proliferated blast-like, lymphoid cell (arrow), non-proliferated lymphoid cells 
(L) and a granulocyte (G) among erythrocytes in a smear of peripheral blood of European eel (Anguilla 
anguilla L., 1758), one day after BrdU treatment. Scale bar = 10 urn. 
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Figure 2. Lymphoid cell proliferation response, presented as mean percentages of BrdU+ lymphoid cells 
in blood smears of fiumequine (FQ)-treated and non-medicated (Control) European eel (Anguilla anguilla L., 
1758; n = 5 per group) after in vivo mitogen stimulation. Bars represent standard deviation. Groups with a 
common superscript do not differ significantly at P<0.050. 
Incorporation of BrdU was only observed in blast-like, lymphoid cells which were 
brown on the slides and hence clearly distinguishable from blue, non-proliferated 
lymphoid cells (Figure 1). Besides, BrdU+ cells were not detected in animals which did 
not receive BrdU. Figure 2 shows the proportions of BrdU+ lymphoid cells in blood 
smears of flumequine-treated and non-medicated groups. Comparison of non-
medicated/BrdU-treated groups revealed that both Con A (P=0.004) and LPS (P=0.027) 
significantly stimulated the proliferation of lymphoid cells. The mean proportion of 
BrdU+ lymphoid cells was significantly elevated by administration of the antibacterial 
drug alone (P=0.035). Following Con A stimulation, the mean relative number of BrdU+ 
lymphoid cells was not significantly different between the flumequine-treated fish and 
the accompanying non-medicated controls; the relative number of BrdU+ cells was 
umilar to that found in drug-treated/non-stimulated animals. The mean mitogenic 
response to LPS was significantly raised in the group treated with fiumequine compared 
with both, the corresponding non-medicated group (P=0.006) and the mitogen control 
group (P=0.012). 
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Figure 3. (a) Forward/side (90°) scatter (FSC/SSC) dot plot of a lymphocyte enriched fraction of peripheral 
blood cells labelled with monoclonal antibody to eel immunoglobulin. Gate contains cells regarded as 
lymphoid cells, (b) Fluorescence histogram of gated cells with marker position used to separate surface 
immunoglobulin positive and negative cells, respectively. 
Table 2. Lymphoid cell proliferation response, presented as mean percentages (SD) of slg+ lymphoid cells 
in peripheral blood of flumequine (FQ)-treated and non-medicated (Control) European eel (Anguilla anguilla 
L.,1758; n=10 per group) after in vivo mitogen stimulation 
FQ-treated 
Control 
Total mean 
+Con A 
+BrdU 
30.74 
(11.39) 
31.06 
(10.07) 
30.92ab 
(11.02) 
+LPS 
+BrdU 
33.48 
(13.28) 
40.31 
(12.34) 
36.90b 
(13.61) 
+PBS 
+BrdU 
21.68 
( 3.50) 
27.44 
( 9.90) 
24.71" 
( 8.32) 
+PBS 
+PBS 
24.42 
( 9.96) 
32.85 
(10.12) 
28.86a 
(11.19) 
Total 
mean 
27.57a 
(11.50) 
32.96b 
(11.83) 
Total mean values with a different superscript are significantly different at P<0.050 within the row or column. 
Figure 3 shows a representative forward/side (90°) scatter dot-plot of a lymphocyte 
enriched fraction of peripheral blood cells and the corresponding fluorescence histogram 
indicating the separation between surface immunoglobulin negative (slg") and slg+ 
lymphoid cells. The mean percentages of slg+ lymphoid cells in peripheral blood of the 
different treatment groups are depicted in Table 2. Statistical analysis revealed no 
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significant influence of BrdU on the proportion of slg+ lymphoid cells. However, a 
significantly lower mean proportion of slg+ cells was observed in flumequine-treated 
animals compared to non-medicated controls. With regard to the combinations of 
mitogen and BrdU-treatment, the mean slg+ cell percentage appeared to be significantly 
higher in animals treated with LPS and BrdU than in animals which received one of the 
other combinations. 
Discussion 
The present study clearly demonstrated that both Con A and LPS induced lymphoid 
cell proliferation in an in vivo experiment with eel. The suitability of in vivo BrdU 
administration for detection of proliferating cells was previously proven in mice (Schutte 
et al, 1987) and humans (Miller et al, 1991). The absence of a significant effect of 
BrdU on the proportion of slg+ lymphoid cells in the present study indicates that the 24 
h exposure to BrdU did not influence the results. 
Traditionally lymphocyte proliferative capacity in fish is only measured by in vitro 
mitogenic stimulation of leucocytes (Rowley et al, 1988). However, an in vivo study 
has the advantage that cell loss or damage due to a cell separating procedure is 
prevented. Cells remain in their natural environment providing all accessory factors for 
optimal proliferation. Moreover, the influence of xenobiotics on lymphocyte proliferation 
can be studied in compliance with the actual kinetics of the substance, including 
possible metabolites or degradation products. 
In mammals, Con A and LPS are respectively considered to be T and B cell 
mitogens (Greaves and Janossy, 1972). In spite of initially conflicting reports (Warr and 
Simon, 1983; Caspi et al, 1984), it became increasingly plausible that these mitogens 
have the same specificity in fish (Koumans-van Diepen et al, 1994). The present results 
support this concept as far as LPS is concerned. The mean proportion of slg+ cells was 
significantly raised in the LPS-treated animals, indicating that this mitogen stimulates, 
at least predominantly, slg+ lymphoid cells in eel. However, the expected reduction of 
the mean proportion of slg+ cells in Con A-treated groups, as a result of the presumed 
T cell stimulation, could not be demonstrated. 
The peroral administration of flumequine proved to be successful as shown by the 
determination of plasma flumequine levels. Interestingly, flumequine seems to possess 
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mitogenic properties because of a significant higher proportion of proliferated lymphoid 
cells compared with untreated animals. According to our knowledge, this phenomenon 
has not been reported so far. It is most probable that mainly slg" lymphoid cells will be 
involved because the proportion of slg+ cells tended to be lower in the flumequine-
treated/non-stimulated groups. In addition, a flumequine induced shift to slg" cells is 
supported by a lower mean proportion of slg+ cells over all flumequine treated animals. 
A synergistic effect of flumequine on the LPS response could be observed. 
However, the stimulating effect of flumequine on lymphoid cell proliferation was not 
reflected in an elevated percentage of slg+ cells, even not when LPS was administered. 
These apparently contradictory results may be explained by the results of Koumans-van 
Diepen et al. (1994) indicating that mainly dull slg+ cells proliferate after LPS 
stimulation of carp leucocytes. Probably the LPS-responding, dull slg+ cells are not or 
only partly recognized as such with the applied flow cytometric detection. 
Counts of BrdU+ lymphoid cells as well as the flow cytometric determination of 
slg+ cells pointed towards an antagonistic effect of flumequine on the Con A response. 
Although differences between individual groups were generally smaller in the 
determination of slg+ cells, an effect of flumequine on lymphoid cell proliferation was 
clearly demonstrated by the statistical analysis. Lymphocyte proliferation occurs in 
lymphoid organs whereas the response was determined in peripheral blood. Whether 
more pronounced changes in slg+ cell proportions occur in lymphoid organs remains to 
be investigated. 
Enumeration of divided lymphoid cells by direct counting of BrdU+ lymphoid cells 
in blood smears was rather laborious, but appeared to be a suitable method which 
revealed more pronounced differences between medicated and non-medicated groups 
than flow cytometric analysis of slg+ cells. However, the latter is a faster, automated 
method. Possibly, flow cytometric determination of incorporated BrdU, whether or not 
combined with simultaneous detection of slg, as described by Koumans-van Diepen et 
al. (1994), offers prospects for combining the advantages of both methods. 
Direct comparison of the present results with those of others is not possible because 
the immunological impact of flumequine treatment is not yet evaluated in vivo. 
However, Miyazaki et al. (1984), who did some toxicological examinations of other 
quinolones in fish, suggested interference of these drugs with DNA synthesis in rapidly 
proliferating cells. Whether this may be related to the alteration of mitogen responses 
in eel by flumequine, is not clear. Delay and inhibition of human lymphoblast 
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proliferation by some quinolones in vitro, as reported by Hussy et al. (1986), does not 
correspond with the present results. 
Immunological tests, like the lymphocyte proliferation assay, give information about 
a particular immunological process occurring at a fixed time during an immune 
response. Although lymphocyte proliferation is essential for an adequate immune 
response, it does not provide insight in the efficacy of the defence system as a whole. 
An effect of drugs on a particular immunological mechanism may be more or less 
compensated or amplified by possible interaction with other immune functions, e.g. 
antigen presentation and non-specific defence systems. Therefore, from a practical point 
of view the overall influence of drugs on the defence system should preferably be 
judged after challenge experiments with relevant pathogens, under conditions which 
mimic actual circumstances. 
From the present study, it is concluded that flumequine enhances proliferation of 
lymphoid cells in eel under the present experimental conditions. However, taking into 
account the risks for development of resistant pathogens, environmental pollution and 
residues in fish destined for consumption, cautious use of this drug is still 
recommended. 
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Abstract 
The effect of the antibacterial drugs flumequine and Oxytetracycline on the defence 
system of European eel (Anguilla anguilla L.,1758) was investigated using an 
experimentally induced infection with the parasitic swimbladder nematode Anguillicola 
crassus. Eight weeks after oral administration of infective larvae, the mean recovery of 
the parasites in flumequine-treated eels was lower than in the non-medicated control 
animals and significantly lower than in oxytetracycline-treated eels. Mean numbers of 
peripheral blood granulocytes and B-lymphocytes as well as the total amount of 
circulating lymphoid cells showed an increase as a result of the infection, while drug 
treatment significantly affected the quantities of the lymphoid cells. The difference in 
protection against the parasite after flumequine or Oxytetracycline administration points 
towards a modulation of the fish resistance as a result of the drug treatment. The results 
favour a modulation of the cellular rather than the humoral response as no specific 
antibodies were found. 
Key-words: Antibacterial drugs, European eel, Resistance, Anguillicola crassus, 
Leucocytes. 
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Introduction 
The antibacterial drugs flumequine and Oxytetracycline are commonly used to 
control bacterial diseases in fish culture. Several studies have shown the interference of 
these drugs with the immune system offish (Rijkers et al, 1980; Rijkers et al, 1981; 
Grondel et al, 1982; Grondel et al, 1985; Grondel et al, 1987; Van der Heijden et al, 
1995a). The latter authors report effects on several immunological processes, such as 
lymphocyte proliferation, antibody production and graft rejection. However, none of 
these studies deals with the actual impact of the drugs on the resistance against 
infectious diseases. 
In European eel, both flumequine and Oxytetracycline are eliminated very slowly 
compared to other teleost species (Nouws et al, 1993; Van der Heijden et al, 1994). 
Consequently, eel is an interesting species for studying side effects of these drugs. To 
evaluate immunomodulating properties of drugs, parasitic infection models are very 
useful, because resistance against parasites is based on a series of, often mutually 
dependent, protective mechanisms (Wakelin, 1984; Roitt et al, 1993), which can thus 
be approached in an integrated way. A parasitic infection model for eel, using 
Anguillicola crassus, a commonly occurring, sanguivorous nematode residing in the 
swimbladder, is already available (Haenen et al, 1989; Boon et al, 1990a; Boon et al, 
1990b; De Charleroy et al, 1990a). This A. crassus model may be suitable for the 
intended challenge test since there is no evidence for any susceptibility of these 
nematodes to antibacterial drugs. Moreover, next to the non-specific reactions described 
by Molnâr et al (1993), data are available for the existence of protective immunity to 
the establishment and development of A. crassus in eel. Boon et al (1990a) 
demonstrated a retarded development of the nematode larvae in the host after repeated 
experimental infections with low numbers of infective larvae of A. crassus. Furthermore, 
both the prevalence of the parasite and the individual nematode burden in large wild 
caught eels from Dutch fresh water lakes have decreased since 1988, whereas this trend 
was not observed in small eels during the same observation period (Haenen et al, 
1994a). In addition, specific humoral antibodies to the parasite in naturally infected eels 
were described by Buchmann et al (1991) and Höglund and Pilström (1994). 
The present report describes an evaluation of flumequine and Oxytetracycline 
treatment of eel with regard to the resistance against an artificially induced infection 
with A. crassus, assessed by determination of the recovery of parasites in the 
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swimbladder, 8 weeks after inoculation. Moreover, during the experiment, A. crassus 
specific antibodies and numbers of granulocytes, lymphoid cells and B-lymphocytes in 
peripheral blood of the host were determined to estimate the activity of the immune 
system. 
Materials and methods 
Fish 
A stock of 100 non-sexed European eels (Anguilla anguilla L., 1758), originating 
from an A. crassus-free eel farm, were kept in the hatchery of 'De Haar - vissen' at the 
Wageningen Agricultural University for about 6 months without using antibacterial 
drugs. Fourteen days prior to the start of the experiment, 80 fish (mean weight ± SD, 
72.6 ± 13.5 g), randomly selected from the stock, were divided into 8 groups of equal 
size. Each group was transferred to a 70-litre aquarium, supplied with non-recirculating, 
aerated tap water of 22.5 ± 1°C (mean ± SD) at a flow rate of about 70 lh"1, for 
adaptation. During the adaptation and experimental period fish were starved. 
Infective larvae 
Infective third stage larvae (L3) of Anguillicola crassus Kuwahara, Niimi et Itagaki, 
1974 (Moravec and Taraschewski, 1988) were produced according to the method 
described by Haenen et al. (1994b). Briefly, L3 were cultured by feeding second stage 
larvae, isolated from wild caught eels, to the intermediate hosts (cyclopoid copepods). 
After 2 weeks, L3 were harvested by crushing the copepods with a tissue potter. 
Subsequently, the released L3 were extracted from the pottered suspension by 
sedimentation in a Baermann funnel. Sixty doses of 12 larvae with 0.5 ml RPMI-1640 
medium (Gibco, Breda, The Netherlands) were prepared in tubes and stored at 4°C until 
the next day. Before use the larval suspensions were substantially shaken after being put 
at room temperature for 2 h. 
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Experimental design 
Each of 4 different treatments was randomly assigned to 2 groups of 10 fish. Two 
of the treatments comprehended administration of flumequine or Oxytetracycline 
respectively, followed by infection with A. crassus. Controls were either only infected 
with the parasite or they were neither medicated nor infected. 
Drug administration and infection technique 
Flumequine (Flumiquil®; Pitman-Moore, Haarlem, The Netherlands) or 
Oxytetracycline (oxytetracycline-HCl; A.U.V., Cuijk, The Netherlands), dissolved in 
physiological salt solution (A.U.V. Cuijk, The Netherlands), were administered by 
injection into the epaxial trunk musculature (i.m.) on both sides of the animal at a dose 
of 10 and 60 mg-kg"1 body weight (BW), respectively. Control animals were sham-
treated by i.m. injection of an equivalent volume (2 ml-kg"1 BW) of the solvent. 
Directly after the injection, each fish was perorally inoculated with either one of the 
previously prepared doses of 12 L3 in RPMI-1640 or merely the medium in case of 
controls. This was done by means of a stomach tube with an attached 1 ml disposable 
syringe. Afterwards, the tubes in which the larvae had been stored were checked for 
possibly remaining larvae to correct the inoculated dose. 
To facilitate the manipulations during injection and infection as well as to prevent 
regurgitation of larvae, fish were profoundly sedated by bathing in 15 ppm metomidate 
(Hypnodil®, Janssen Parmaceutica B.V., Beerse, Belgium) for about 20 minutes. 
Sampling 
From 2 until 6 weeks post infection (p.i.), heparinized blood samples of 0.5 ml were 
collected weekly from each eel by puncturing the caudal vein after sedation (5 min in 
15 ppm metomidate). After preparing blood smears, the samples were centrifuged 
(300xg, 10 min at 4°C) and plasma was stored at -20°C. The buffy coat was collected 
and stored on ice until further processing. 
At 8 weeks p.i., eels were bled and plasma was obtained and stored as described 
above. Subsequently, the animals were euthanized by decapitation, the swimbladders 
were extirpated and examined for the numbers and developmental stages (Boon et al., 
1990a) of parasites present in the lumen or wall. 
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Peripheral blood leucocytes (PBL) 
Blood smears 
The air dried blood smears were fixed in methanol for 5 min, stained according to 
the May-Grünwald-Giemsa method (Romeis, 1968), dehydrated and embedded in 
DePeX (BDH, Dorset, UK). The relative abundance of the different white blood cell 
types (Boon et al, 1990b) was determined after differential counting of a total of 100 
leucocytes per smear at a magnification of lOOOx. 
Flow cytometry 
The collected buffy coat cells were purified by centrifugation over Lymphoprep® 
(Nycomed, Oslo, Norway) for 30 min at 1500xg and 4°C. PBL harvested from the 
interface were washed twice with eRPMI (65% RPMI-1640 + 10 IU-ml"1 heparin + 
0.1% (w/v) NaN3 + 1% (w/v) BSA; pH 7.4, 240 mOsm-kg') by centrifuging for 10 min 
at 680xg and 4°C. Subsequently, the isolated PBL were resuspended in 1 ml eRPMI, 
counted by means of a Coulter Counter® (model ZM; Coulter Electronics Ltd, Luton, 
UK) and diluted to a density of 2xl06 cellsml"1. The percentage of surface 
immunoglobulin positive lymphoid cells (B cells) was determined with a FACStar® flow 
cytometer (Becton Dickinson, Mountain View, CA, USA), using a mouse monoclonal 
antibody specific for eel immunoglobulin (Ig) heavy chain (WEI 1; 1:400; Van der 
Heijden et al, 1995b) and fluorescein isothiocyanate conjugated rabbit anti-mouse Ig 
(RAM-FITC; 1:100; Dakopatts, Glostrup, Denmark) as second antibody. Lymphoid cells 
were gated and analyzed for labelling using the Consort 30 data analysis package. 
The absolute number of cells in PBL subpopulations was estimated by combining 
the data obtained by Coulter Counter®, FACStar® and differential leucocyte counts. 
ELISA for detection of antibodies to A. crassus 
Plasma samples collected at 3 weeks p.i. were used individually, whereas those from 
2, 4, 5, 6 and 8 weeks p.i. were pooled per group. Screening for A. crasms-specific 
antibodies was done using an ELISA according to Hoglund and Pilstróm (1994) with 
some modifications. In summary, high affinity microtiter plates (Greiner, Alphen a/d 
Rijn, The Netherlands) were coated with whole worm extract purified by isoelectric 
focusing and post-coated with 5% (w/v) lean milk powder in 0.5% (v/v) Tween 20-
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containing phosphate buffered saline. After washing, plates were successively incubated 
with serial dilutions of plasma samples, a mouse monoclonal antibody specific for eel 
Ig light chain (WEI 2; 1:200; Van der Heijden et al, 1995b) and rabbit anti-mouse Ig 
conjugated with horseradish peroxidase (RAM-HRP; 1:5000; Dakopatts, Glostrup, 
Denmark). HRP was demonstrated using a substrate solution consisting of 
tetramethylbenzidine and H202 in acetate/citrate buffer. After 10 min, the reaction was 
stopped with 0.5 M sulphuric acid. The resulting absorbence was recorded at 450 nm 
in an Easyreader spectrophotometer (SLT-labinstruments, Vienna, Austria). To correct 
for plate differences each plate contained the positive and negative control sera 
described by Höglund and Pilström (1994). 
Determination of antibacterial drugs 
Plasma samples collected at 2 weeks p.i. were pooled per group and checked for the 
presence or absence of flumequine and Oxytetracycline by column-switching high 
performance liquid chromatography. The flumequine determination was carried out 
according to the method described by Van der Heijden et al (1994). Oxytetracycline 
was determined after concentration from diluted plasma using a column packed with 
Sep-Pak C-18 material (Waters, Millford, MA, USA) and subsequent separation on an 
Inertsil ODS-2 analytical column (Chrompack, Bergen op Zoom, The Netherlands). UV 
detection was performed at 365 nm. 
Statistical analysis 
Data are presented as mean values ± standard error of the mean (SE). The numbers 
of A. crassus retrieved, the recovery (number of parasites retrieved divided by corrected 
number of L3 administered) and the occurrence of different developmental stages of the 
parasite in the infected groups were examined by analysis of variance (ANOVA), using 
the factors fish, group, treatment and their interactions. Data on estimated numbers of 
granulocytes, lymphoid cells and B cells were first tested for outliers by means of box 
plots. Thereafter, the remaining data were subjected to ANOVA across weeks (factor 
time in addition to factors mentioned above) and ANOVA within weeks (model as 
above). Where possible the models were reduced by omitting non-significant interaction 
terms. After ANOVA, the least significant difference method (LSD-T test) was 
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employed forpairwise comparison of means. STATISTIX (1985) software was used for 
all statistical analyses and differences were considered to be significant at a probability 
of 0.050 or less. 
Results 
Medicated groups were positive for the injected flumequine or Oxytetracycline. At 
2 weeks p.i., the respective mean drug concentrations in plasma of those animals were 
approximately 0.2 and 10 u-g-ml'1, while neither of both drugs could be detected in the 
non-medicated groups. 
The number of A. crassus retrieved at the end of the experiment in the flumequine-
treated fish (1.2 ± 0.5) was lower than in the non-medicated controls (2.2 ± 0.5) and 
appeared to be significantly lower than in the oxytetracycline-treated animals (2.9 ± 0.6). 
Swimbladders of sham-infected eels contained neither larval nor adult specimens of the 
parasite. The corrected mean doses of L3 were 11.8 for the medicated groups and 11.4 
for the infected, non-medicated groups. This lead to recoveries as shown in Figure 1. 
Flumequine treatment resulted in a 48.8% reduction of the recovery relative to the 
controls and a significant 60.6% reduction compared to Oxytetracycline treatment. The 
proportion of different developmental stages (L3, fourth stage larvae, pre-adult or adult) 
in the recovered A. crassus population per treatment is presented in Table 1. ANOVA 
did not reveal an influence of the drugs on the development of the parasite larvae. L3 
were not found at all, whereas adult parasites always comprised about 70 to 80% of the 
worm burden. 
Figure 2 shows the estimated numbers of granulocytes, lymphoid cells and B-
lymphocytes in peripheral blood of the non-medicated groups during the experiment. 
The influence of the parasite infection was clear because the mean counts of the 
different leucocyte types were consistently higher in the infected animals. Comparison 
across weeks showed a significant influence of the infection on lymphoid cell and B-
lymphocyte numbers. Furthermore, there was a significant time effect on all parameters. 
In week 3, 4 and 6 p.i. the mean numbers of lymphoid cells were significantly higher 
in infected eels, while the granulocyte and B cell counts of these fish were significantly 
higher at 3 and 4 weeks p.i., respectively. 
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Figure 1. Mean recovery percentage of inoculated Anguillicola crassus in flumequine or Oxytetracycline 
treated and non-medicated (Control) European eels (Anguilla anguilla L., 1758; n=20 per treatment) at the end 
of the experiment. Bars represent the standard error of the mean. Groups with a superscript in common do not 
differ significantly at P<0.050. 
Table 1. Mean percentage (± SE) of the different developmental stages of Anguillicola crassus in relation 
to the total worm burden for the various treatments at the end of the experiment 
Treatment* 
Drug Inf. 
FQ + 
OTC + 
+ 
-
L3 
0.0 ± 0.0 
0.0 ± 0.0 
0.0 ± 0.0 
NP 
Developmental stage 
L4 
0.0 ± 0.0 
7.1 ± 4.0 
3.7 ± 3.7 
NP 
Pre-adult 
21.7 ± 11.7 
20.0 ± 14.4 
27.8 ± 5.6 
NP 
Adult 
78.3 ± 11.7 
72.9 ± 10.4 
68.5 ± 1.9 
NP 
* n=20 per treatment. Abbreviations: Inf., infection with A. crassus; L3, third stage larvae; L4, fourth stage 
larvae; FQ, flumequine; OTC, Oxytetracycline; NP, not present. 
The estimated number of cells in the aforementioned PBL subpopulations for the 
infected groups is depicted in Figure 3. Once more, there appeared to be a significant 
influence of time on each of these parameters, but an overall treatment effect was not 
found. However, at 3 weeks p.i. the mean numbers of both lymphoid cells and B-
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lymphocytes were significantly raised in oxytetracycline-treated animals in comparison 
with those treated with flumequine. 
Specific antibodies to the parasite were not demonstrated in any of the plasma 
samples analyzed. All samples showed ELISA optical densities corresponding with the 
negative control sera, while positive control sera showed a clear reaction. 
Discussion 
Plasma drug concentrations measured in the present experiment at 2 weeks after 
injection are in accordance with those reported in previous studies on the kinetics of 
flumequine (Van der Heijden et al, 1994) and Oxytetracycline (Nouws et al, 1993) in 
eel. This means that demonstrable concentrations of the drugs will be present in the eel 
tissues for at least 4 to 6 weeks after administration. So, a possible influence of the 
drugs on the defence mechanisms may be assumed during the same period. Moreover, 
this time span coincides with the expected residence of L3 in the tissues and their 
migration from the lumen of the digestive tract to the swimbladder (Haenen et al, 1989; 
De Charleroy et al. 1990b). The resulting most intimate contact between the host 
immune system and the parasites will be the major stimulus for resistance. Therefore, 
the arrival of A. crassus in the swimbladder will be dependent on the condition and 
functioning of the (compromised) defence system during the larval migration phase. This 
means that the recovery of the nematodes, as recorded in this study, provides an 
indicator for drug associated immunomodulation. 
The percentage of worms retrieved in swimbladders of non-medicated eels was 
approximately 20% of the dose administered, which is somewhat lower than the 25% 
found by Boon et al. (1990a) and the 38% found by De Charleroy et al. (1990a). 
However, the larvae they used for infection were taken from infected glass eel and carp, 
respectively. As a consequence, these L3 were more or less selected for viability because 
they had proven to be able to penetrate the tissues in an intermediate or final host. 
The recovery of the worms in the present experiment ranged from about 10% in 
flumequine-treated eels to almost 25% in the oxytetracycline-treated animals. The higher 
recovery in the latter group compared to the controls may be explained by the 
immunosuppressive effects attributed to Oxytetracycline (Rijkers et al, 1980; Rijkers et 
al, 1981; Grondel et al, 1982; Grondel et al, 1985; Grondel et al, 1987). On the other 
106 
|LU j a d ( 9oi - x ) se iAooqdu jA | -g 
|LU tad (gOl*) s i ieo p!Ou;dujA-| 
l -s 
£'6 
<» s 
(U o 
8 « 
f c 
o. — 
I ö 
j ï x t s 
na „ 
•o • * 
vi ™ 
•O M 
S I 
„ vi ^-v Ô ^ ° cd ,—. in 
- a "> 
1 l-i 
2 O M 
M > 
<•- - S 4> 
° ~ -S 
u So e 
x i c u 
-Ç » J5 
I ë 
|UJ jad (gOl-X) sa;AooqduJA|-g 
O O 
1LU J3d ( 90l - x ) S||9D pjoydLuAi 
|uu j a d ( 9 0L X ) sa iA3O|nue j0 SI« to BJ ^ 
l i 
'IS 
S/3 
o.—: 
2 .o, 
S Si 
3 (N 
x 6 6 
<K o VI 
° * fc. 
"O ^ .-
73 I M 
•c te .a 
U C -o 
o. o u 
73 ° s 
8. S -
u <u 
A 3 '5 
U te _ 
-O « <-
ö s?a 
43 o e 
- ó i. -o 
0 .S o 
3 3 <N 
S ST«« 
1 | o 
5 | 
1 S 
Üß 
|LU j a d (gOl-X) ssiAoo|nuej£) 
-o o 
'.
 ö
 E 
£ S i 
ais 
Chapter 6 
hand, there are indications that flumequine enhances proliferation of surface 
immunoglobulin negative (slg") lymphoid cells (Van der Heijden et al, 1995a). This may 
account for the lower nematode recovery in the flumequine treated fish, the more so as T-
lymphocytes and natural killer cells, both slg" lymphoid cells, are assumed to fulfil a key 
role in the immunological responses against most parasitic pathogens (Wakelin, 1984; Woo, 
1992; Roitt et ai, 1993). 
Due to large variation in worm burden within groups, the difference between parasite 
recoveries in the drug-treated animals and the controls was not significant in spite of 
considerable differences in the mean recovery. As resistance against parasitic infections of 
both mammals (Wakelin, 1985) and fish (Bower and Margolis, 1984; Wiegertjes et al, 
1995) appears to be dependent on the genetic constitution of the host, the individual 
variation in worm burden in the present study might be attributed to assumed large genetic 
variation within eel populations. 
Activation of the eel immune system as a result of the presence of A. crassus in the 
tissues was illustrated by increased numbers of circulating leucocytes. This quantitatively 
substantiates the previously reported influence of A. crassus infection on the relative 
abundance of these cells (Boon et al, 1990b). However, a time effect on PBL numbers 
during the experiment could be observed for infected as well as for non-infected animals. 
This probably indicates that a certain degree of stress, caused by the experimental 
procedure, has influenced the leucocyte counts as well (Pickering, 1986). 
Comparison of the drug treatments showed a significant difference in lymphoid cell and 
B-lymphocyte counts at 3 weeks p.i. These PBL counts obviously correlated with the A. 
crassus recovery data (r=0.908 and 0.840, respectively; P<0.050), suggesting that the 
numbers of lymphoid cells are not only influenced by the drugs but possibly also by the 
worm load. However, the recovery was determined 8 weeks p.i. and mainly consisted of 
adult and pre-adult stages retrieved from the swimbladder lumen, which may be considered 
an immune privileged site because of the remoteness from any of the immediate effectors 
of resistance. Nevertheless, a higher recovery will have been preceded by a higher number 
of active, tissue-dwelling larvae, leading to an increased reaction of the immune system. 
Specific antibodies to A. crassus were not found in the present study. This seems to be 
in contrast with the results of Buchmann et al. (1991) and Höglund and Pilström (1994) 
who demonstrated anti-A crassus antibodies in serum of naturally infected fish or fish 
intraperitoneally injected with adult whole-worm extract. However, the amount of antigen 
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in their respective studies was much higher than in the present case, where a single oral 
infection with about 12 L3 was used. This dose might be too low to elicit a measurable 
primary antibody response, all the more because it can not be excluded that part of the L3 
administered did not penetrate the digestive tract epithelium. Conversely, assuming that all 
inoculated L3 actually entered the eel tissues and taking into account that only about 10 to 
25% was recovered from the swimbladder, there are still around 10 larvae left. These larvae 
would constitute a considerable antigen source for the host, especially after their death and 
subsequent disintegration. If this is the case, the absence of specific antibodies should 
probably be explained by development of latent or encapsulated larvae (Molnâr, 1994), 
which will be less immunogenic. Furthermore, the feed deprivation of the experimental 
animals during the present study, but also stress caused by this or otherwise, may have 
played a role by suppression of antibody production (Henken et al., 1987; Ellis, 1981). 
Meyer (1989) suggested a broad spectrum activity of quinolones (e.g. flumequine) 
against bacteria, as well as fungi, protozoans and helminths without providing any evidence. 
His statement might be based on immunostimulation by these drugs, as a direct effect on 
such a broad spectrum of pathogens, without severe adverse effects on the target animal, 
is very improbable. Although the present experimental design does not exclude a direct 
influence of the drugs on the nematodes, it is more likely that the difference in protection 
against A. crassus in flumequine- and oxytetracycline-treated eels is due to a modulation 
of the fish resistance by these drugs. In this respect it is worthwhile to mention that the 
mean number of white spots, on flumequine-, furazolidone- and sham-treated groups of eels, 
after an accidental infection with the protozoan parasite Ichthyophthirius multifiliis in our 
laboratory, appeared to be significantly lower on flumequine-treated animals (unpublished 
results). 
In conclusion, a better protection against A. crassus is achieved in eels treated with 
flumequine compared to those treated with Oxytetracycline. This difference seems to be 
related to an influence of these drugs on the fish defence system. The present results point 
to a modulation of the cellular rather than the humoral response as no specific antibodies 
against the nematode could be detected. 
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Introduction 
A disproportionate increase in the use of antibacterial drugs in relation to 
production, as came along with the expansion of the intensive fish culture (chapter 1 ), 
took previously place after the introduction of intensive farming techniques in traditional 
animal husbandry. Considering the promising developments in the latter industry (Van 
den Bogaard et al, 1994), the phenomenon should probably be regarded as an initial 
attempt to restore the disrupted balance between host and pathogen. This imbalance 
results from both decreased resistance of the intensively farmed animals and ready 
transmission of pathogens in the densely stocked populations. These latter factors which 
combine to favour disease are also factors which hinder easy control of disease. 
Nevertheless, the increasing need for sustainable production methods asks for emphasis 
on disease prevention rather than on treatment as the primary focus of health 
management. Simply increasing the use of antibacterial drugs does not really solve the 
problems associated with bacterial diseases; it may even mask deficient farm 
management while additionally carrying a significant risk for the consumer, the 
environment and the target animals themselves (chapter 1). Therefore, attention should 
be paid to a strict hygiene and improvement of the general health condition of the 
animals through further optimization of husbandry techniques along with application of 
appropriate monitoring systems. Moreover, application of vaccines and/or 
immunostimulants may also contribute to prevent disease related production losses. 
Preventive measures as mentioned above, could reduce outbreaks of bacterial 
diseases in aquaculture and thus the need for antibacterial drugs. However, if prevention 
is not effective, the use of antibacterial drugs is a last resort, and as such these drugs 
form an indispensable part of fish health care. Unfortunately, in most fish farming 
countries the number of drugs registered for use in fish is not in proportion to the 
production volume of the sector and usually insufficient to warrant an optimal disease 
treatment. In some countries, including The Netherlands, even no drugs are fully 
approved for use in food fish (Anonymous, 1992). The resulting, inevitable off-label or 
unauthorized use of drugs constitutes an unmistakable problem for the aquaculture 
industry through a lack of necessary specific knowledge. Next to increasing concerns 
about antibacterial drug resistance, potential effects of drug residues in food and 
environmental pollution, little is actually known about the impact of drugs on the health 
and associated disease resistance of treated animals. This also applies to the use of 
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flumequine in Dutch eel culture, which is the common theme of the experiments 
presented in this thesis. 
In the current chapter the main results of the constituent papers of this thesis will 
be briefly summarized and discussed in a broader context. Attention will be paid to 
matters that were previously underexposed and to the implications of some aspects for 
fish culture in general and the culture of European eel in particular. Moreover, some 
recommendations for further research will be made. The respective chapters should be 
consulted for complete results with accompanying more detailed discussions. 
On the kinetics of flumequine 
Pharmacokinetic data are indispensable to estimate the clinical efficacy of a drug 
as well as its possible negative effects. Accordingly, the series of experiments in the 
present thesis opens with a couple of studies on the disposition kinetics of flumequine, 
a drug commonly used in intensive aquaculture production systems and the central drug 
in further experiments. 
Interspecies differences with regard to the plasma disposition after a single peroral 
administration of flumequine were studied in common carp, African catfish and 
European eel. All species showed an unexpectedly rapid absorption after peroral 
administration of the drug, which lead to a lack of data for a proper characterization of 
the absorption phase. This might be connected with the fact that the drug was presented 
in dissolved form, which might have influenced the rate of absorption. In contrast, 
intramuscular administration of a flumequine suspension to European eels resulted in a 
much slower absorption (chapter 3; Boon et al, 1991). During the subsequent 
distribution and elimination phases the plasma flumequine concentrations of the 
individual fish fitted well into a two-compartment open pharmacokinetic model. 
However, statistically significant interspecies differences were observed for most of the 
determined pharmacokinetic parameters concerning these phases. Moreover, the results 
demonstrated an extremely slow elimination of flumequine in European eels. 
It went beyond the scope of this thesis to find an explanation for this most 
intriguing slow elimination of flumequine in eels. However, several reasons can be put 
forward which may contribute to this phenomenon. 
(1) On average eels have an exceptionally high body fat content (Heinsbroek et al, 
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1989; Garcia-Gallego et al, 1993; Heinsbroek et al, 1993). Considerable quantities of 
substances with high lipid solubility - like flumequine - may be stored in this fat (De 
Boer and Pieters, 1991). Once assimilated in fat, these substances are usually slowly 
released from this depot, which is partly due to the poor vascularization of this tissue. 
However, this theory was not supported by tissue analyses (chapter 3). Despite the 
highest flumequine concentrations were initially found in fat tissue, a comparatively 
rapid decline was observed. In addition, there were no indications for accumulation of 
flumequine in any other tissue examined. However, good tissue distribution and the slow 
release from tissues, especially bone and skin, will play a role in the slow elimination 
from plasma. 
(2) Almost no biotransformation of flumequine was observed in eel nor in carp and 
catfish (chapter 2). This agrees with the results obtained by Sohlberg et al. (1990), who 
did not find any metabolites of flumequine after oral and intra-arterial administration of 
the drug to rainbow trout. Moreover, after intramuscular injection of flumequine in eel 
more than 85% of the dose administered was recovered in the holding water in 
unchanged form (Boon et al, 1991). Nevertheless, several flumequine metabolites (7-
hydroxy-flumequine and glucuronide conjugates) have been reported in mammals 
(Mevius, 1990). In principle, the same metabolites should be expected in fish because 
the current knowledge confirms the existence of xenobiotic metabolizing enzyme 
systems in these animals with striking similarities with their mammalian analogues 
(Guarino, 1986). 
(3) Possible absence of active renal (tubular) excretion of flumequine in eels, as 
previously suggested by Boon etal. (1991). The relative importance of passive excretion 
processes in the latter study was supported by a strong correlation between the pattern 
of the plasma concentration and the excretion ((xg-kg^h"1) of the drug. Generally, renal 
excretion is assumed to be of minor importance for the elimination of drugs in fish. This 
is believed to mainly depend on diffusion from the capillaries in gills (and possibly skin) 
into the surrounding water and on hepatic excretion (Hickman and Trump, 1969). The 
gill surface of eels is comparatively small as opposed to other fish species (Byczkowska-
Smyk, 1958), which may play a role in the extremely slow elimination of flumequine 
in this species. 
(4) Entero-hepatic recirculation, which is reported for several quinolone drugs in 
mammals (Schentag et al., 1990). Although there were no direct indications for biliary 
excretion of flumequine in eels nor for a subsequent reabsorption from the intestinal 
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tract in the studies performed, the long persistence of the drug may well be related to 
this phenomenon, because of the rapid flumequine absorption from the gastro-intestinal 
tract and the relatively high concentrations of this drug found in liver tissue (chapter 3). 
Considering that the afore mentioned aspects may play a role in the observed long 
elimination half-life of flumequine in eels, further research to elucidate the underlying 
causes is highly recommended. 
On the impact of flumequine 
Health parameters 
It is difficult to quantify the health condition of an animal. However, since many 
cases arise in which some degree of health assessment is desired, several authors made 
an effort to define parameters that can be used to describe the physical well-being of 
animals (Blaxhall, 1972; Miller et al, 1983; Wedemeyer et al, 1983; Pickering and 
Pottinger, 1988; Anderson, 1990; Goede and Barton, 1990; Novotny and Beeman, 1990; 
Schreck, 1990; Iwama et al, 1995). So far, parameters related to various disciplines 
(e.g. ethology, endocrinology, haematology, immunology) as well as interdisciplinary 
approaches have been advocated. In the present thesis research was focused on the 
functioning of the defence system and associated disease resistance, because antibacterial 
drugs are known as potential immunomodulators (Grondel and van Muiswinkel, 1986; 
Descotes, 1988). Moreover, some of these drugs proved to be very slowly eliminated 
by European eels (chapters 1, 2, 3), which may increase the significance of any side 
effects in this particular species. 
To evaluate the possible interference of flumequine with the defence system of 
European eel, essentially three different approaches were used in the studies presented. 
A shift in the ratio or numbers of different peripheral blood leucocytes was assumed to 
point towards a modulation of the defence system. In this respect, special attention was 
given to the relative abundance of surface immunoglobulin positive (B) lymphocytes. 
Furthermore, the proliferative capacity of lymphocytes was assessed by means of a 
lymphocyte proliferation assay using a presumed B cell (lipopolysaccharide; LPS) or T 
cell (concanavalin A; Con A) mitogen (Roitt et al, 1993). Finally, an experimental 
infection with the parasitic swimbladder nematode Anguillicola crassus was performed 
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to address the impact of the drug on the total resistance of the exposed host. 
Partially the necessary tools yet had to be developed. To this end, monoclonal 
antibodies (mAbs) to immunoglobulin (Ig) of European eel were produced (chapter 4). 
The selected mAbs, designated WEI 1 and WEI 2, proved to be specifically reactive to 
the Ig heavy and light chain, respectively. Testing of the reaction pattern using various 
immuno(cyto)chemical techniques revealed that WEI 1 probably recognizes all Ig 
molecules, whereas WEI 2 reacts with part of them. Nevertheless, using either of the 
mAbs, similar titres were achieved in enzyme-linked immunosorbent assays (ELISAs) 
for detection of plasma Ig. Consequently, a possible difference in background should be 
decisive in the selection of the most appropriate mAb for this application. With regard 
to immunocytochemistry, however, there appeared to be a clear difference in the 
percentage of cells labelled by WEI 1 or by WEI 2. Obviously, WEI 1 was considered 
to be the most suitable reagent for routine monitoring, most if not all, Ig-bearing (B) 
lymphocytes. 
Flow cytometric determination of B-lymphocyte proportions in peripheral blood 
turned out to be an adequate method for preliminary establishment of immune 
alterations in fish (chapters 5, 6). The procedure is comparatively fast, so the rather 
large variation in this parameter can easily be countered by adapting the sample size 
accordingly. Moreover, since the animals do not have to be sacrificed, there is a 
possibility to follow the developments in individual animals over time. However, 
although a shift in the proportion of B-lymphocytes (and hence in the complementary 
fraction of Ig negative lymphoid cells) definitely reflects a change in immune status, 
additional tests are required to assess the possible positive or negative influence on the 
animals health. 
The proliferative capacity of lymphocytes is generally measured by means of in 
vitro assays using stimulation with mitogens or allogeneic leucocytes and incorporation 
of tritium thymidine into DNA. Although these tests are very sensitive several 
disadvantages were recognized. Specific laboratory equipment suitable for the use of 
isotopes is needed and, more important, the cells are cultured in a highly unnatural 
environment, which may hamper the interpretation of the results. Therefore, preference 
was given to development of a more realistic, in vivo counterpart of the mitogen 
mediated lymphocyte proliferation assay (chapter 5). Essentially, this test includes 
intraperitoneal injections of mitogen and 5-bromo-2'-deoxyuridine (BrdU). The latter 
is incorporated into DNA of dividing cells, which are enumerated in blood smears after 
119 
Chapter 7 
immunocytochemical detection of BrdU. All in all this in vivo method appeared to be 
a useful technique for assessment of the ability of different lymphocyte subpopulations 
to respond to mitogenic activation. 
Influence on the defence system 
A limited number of studies is available concerning the effects of some quinolones 
on immune functions in man, rats and mice (Descotes, 1988; McDonald and Pruul, 
1990). These comprehensive reviews report studies which mainly relate to in vitro tests 
regarding mitogen induced T-lymphocyte proliferation and several phagocyte functions, 
including antigen uptake, superoxide production, intracellular killing and Chemotaxis. 
The results ranged from suppression to no effect or stimulation of these functions 
depending on the type of drug, the species and the experimental target parameter used. 
However, overall it was concluded that although some quinolones modify certain in 
vitro immune functions, these changes are relatively small and do not have in vivo 
correlates. In other words there is no evidence that any of the quinolones tested may 
lead to clinically relevant immunomodulation in mammals. In fish, research on 
immmunomodulating effects of quinolones is even more scarce than in mammals, while 
such information with regard to flumequine was completely lacking at the start of the 
present study. 
Therefore and in view of the common use of flumequine in Dutch eel culture, it was 
decided to study the influence of this drug on the in vivo proliferative capacity of 
peripheral blood lymphoid cells in eels (chapter 5). The LPS response appeared to be 
enhanced by the drug, whereas a slight, but not significant, decrease was observed in 
the response to Con A after flumequine treatment. Moreover, flumequine proved to 
posses mitogenic properties by itself since the proportion of proliferated cells was 
significantly increased in comparison with untreated animals. Taking into account that 
flow cytometric analyses showed a significant reduction of the percentage of surface Ig 
positive (slg+) lymphoid cells in flumequine treated animals, the results point to a 
potentiation of slg" lymphoid cells by this drug. The latter agrees with the observation 
that flumequine did not significantly affect the production of circulatory antibodies 
against the intramuscularly injected antigen DNP-KLH (dinitrophenyl-keyholelimpet 
haemocyanin) in eel, as measured by ELISA (Van der Heijden et al, 1994a). 
Recently, Boon et al. (1996) reported a significant stimulation of the metabolic 
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activity of peripheral blood phagocytes in eel, after flumequine injection and subsequent 
ex vivo measurement of nitro blue tetrazolium dye reduction by those cells. Upon 
stimulation, mammalian phagocytes show an enhanced production of cytokines such as 
interleukin 1 (IL-1) and tumour necrosis factor (TNF), which directly and indirectly 
activate lymphocytes and themselves (Roitt et al, 1993). IL-1 has been shown to 
potentiate both the specific and non-specific defence of mice due to its ability to activate 
T-lymphocytes (Cheers et al, 1990). There are several indications that quinolones elicit 
production of certain cytokines, principally IL-1 and TNF, in human and rodent 
phagocytes (McDonald and Pruul, 1990; Bailly et al, 1991; Stünkel et al, 1991). 
Unfortunately, comparable data for fish are not available. However, in view of the 
observed immunostimulatory effects, it seems plausible that similar processes may occur 
in eel as both IL-1-like and TNF-like molecules have been demonstrated in other teleost 
species (Secombes, 1991; Ahne, 1993; Verburg-van Kemenade et al, 1995). 
Nevertheless, to confirm the supposed mechanism for the effect of flumequine on the 
defence system in eel, additional experiments are required in which the relevant cytokine 
levels as well as their influence on leucocytes have to be determined in the species 
concerned. 
The immunomodulatory effects of flumequine, presented above, are in accordance 
with results of Siwicki et al. (1989), who report a metabolic activation of spleen 
neutrophils in rainbow trout immunized with Yersinia ruckeri O-antigen after injection 
of, the structurally related, oxolinic acid at doses from 0.1 to 10 mg-kg"1 BW. 
Unfortunately, they did not provide any data on the influence of the drug on the 
proliferative capacity of lymphoid cells. However, monitoring the specific immune 
response by means of a hemolytic plaque assay revealed that the numbers of antibody-
producing cells were not significantly affected by the quinolone they used. 
Disease resistance 
The defence system is an exquisitely balanced, highly complex system involving an 
elaborate regulatory network and functionally interdependent immunocompetent cell 
populations. Alterations in this balance, being either depression or enhancement of a 
particular element, may be compensated or amplified by additional interactions or 
immunological feed back mechanisms (Van Loveren and Vos, 1991). As a consequence, 
the practical relevance of observed immunomodulation in terms of disease resistance can 
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not automatically be deduced from a statistically significant effect of a substance on 
defence mechanisms like e.g. phagocyte killing efficiency, antibody production or 
lymphocyte proliferation (chapter 5). In fact, any sound interpretation of such data 
should be based upon the observation that fixed criteria have been met in the course of 
exposure. But generally accepted critical values for immune alterations are not available 
yet. Therefore, challenge tests will have to be performed to evaluate the predictive 
significance of basic immunological changes towards disease resistance. 
Over the last decade quite a number of studies has been dedicated to infections of 
European eel with the commonly occurring parasitic swimbladder nematode Anguillicola 
crassus. As a result of these studies, a gradually optimized , well functioning infection 
model of A. crassus in European eel became available (Haenen et al, 1989; Boon et al, 
1990a; Boon et al, 1990b; De Charleroy et al, 1990). In chapter 6 a challenge study 
using experimental infection of flumequine- or oxytetracycline-treated European eel with 
this parasite, is described. The percent recovery of parasites in the swimbladder, 8 weeks 
after inoculation, was used to quantify some association between drug treatment and 
host resistance. The experiment ultimately revealed a parasite recovery in flumequine-
treated eels which was considerably lower than in non-medicated controls and 
significantly lower than in eels treated with Oxytetracycline. These results indirectly 
affirm the enhancement (chapter 5) and impairment (Rijkers, 1980; Grondel, 1986) of 
the fish defence system by the respective drugs, while they simultaneously demonstrate 
the relevance of this influence for the protection against an invading pathogen. 
The observed differences in protection against A. crassus indicate the suitability of 
this challenge model for assessment of the impact of immune alterations in European 
eel. Unfortunately, the exact mechanisms involved in resistance against A. crassus are 
not yet fully elucidated (Haenen, 1995). So, the model must actually be regarded as a 
'black box'; the infection dose is known and the resulting nematode burden can easily 
be determined, but everything happening in between remains to be investigated. This 
flaw was recognized and might have been largely avoided by using a bacterial challenge 
model, since the existing knowledge on immunity of fish against bacterial infections is 
generally on a much higher level. However, living bacteria could not be used in the 
present case, because a possible toxic effect of the antibacterial drugs on the microbes 
would interfere with the results. On the other hand, application of killed bacteria or 
bacterial fractions, as an obvious alternative, was considered to be too remote from a 
natural challenge to yield meaningful information on the degree to which fish can really 
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resist infections. 
A. crassus infestations in European eels were reported to be accompanied by a shift 
in the peripheral white blood cell picture of the host (Boon et al, 1990b; Höglund et 
al, 1992) and by production of specific antibodies (Buchmann et al, 1991; Höglund and 
Pilstró'm, 1994). Consequently, during the challenge study with this parasite (chapter 6), 
the above parameters were chosen to monitor the course of the host reaction, as well as 
the influence of the drugs upon this process. The leucocyte counts (i.e. granulocytes, 
total lymphoid cells and B-lymphocytes) were indeed clearly raised by the infection, 
which is indicative of a humoral and cellular response to the parasite. However, despite 
significant differences, changes in the numbers of leucocytes were difficult to interpret 
as far as effects of the drugs are concerned. Furthermore, anti-A crassus antibodies 
could not be demonstrated, irrespective of the antibacterial treatment. This absence of 
a specific humoral response against A. crassus after a single experimental (re)infection 
was confirmed by Haenen et al (1995). Recent results indicate that multiple reinfections 
(at least twice weekly for 4 weeks; K. Knopf, pers. comm.) are required to elicit 
demonstrable specific antibody titres under experimental conditions. 
The fact that specific antibodies were not found implies that the drug-induced 
difference in resistance against A. crassus has to be attributed to an effect on other 
forms of defence. This supports an actual causative connection between the improved 
protection in eels treated with flumequine and the apparent immunostimulating 
properties of this drug, which relate to cellular (chapter 5) and non-specific (Boon et al, 
1996) defence mechanisms. Accordingly, it is concluded that flumequine may augment 
resistance against infections in eel through a beneficial effect on the defence system. 
Use of antibacterial drugs in eel culture 
Unlike in Japanese pond culture of eels, bacterial disease problems in European eel 
reared under controlled conditions in closed recirculation systems are mainly attributed 
to facultative fish pathogenic bacteria, whose pathogenicity depends on the quality of 
the environment and the associated fish health condition. This means that at least the 
majority of the bacterial diseases of European eel may be prevented. As indicated 
previously, good farm management, including water quality control, strict hygiene and 
regular health monitoring (providing the possibility of early intervention), is crucial in 
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this situation. Prophylactic administration of antibacterial drugs is usually neither 
feasible nor sensible because the problems are predominantly caused by ubiquitous 
bacteria, which will quickly recover once the drug concentration drops below their 
minimum inhibitory concentration. Next to a small chance for success, this procedure 
additionally carries the disadvantages known to be associated with the use of drugs. 
Notably the risk of development of drug resistant bacterial pathogens may have serious 
consequences if disease really strikes. 
In case of an (acute) outbreak of bacterial disease, treatment with antibacterial drugs 
may be necessary to lower mortalities and to allow partial recovery of the fish. 
However, such treatment is not likely to be effective without supporting environmental 
optimization, while the use of immunosuppressing drugs may further weaken the 
immunocompromised animals. Moreover, to achieve satisfying results, (confirmation of) 
drug selection should be based on drug sensitivity tests with the isolated pathogen and, 
of course, on the pharmacokinetic characteristics of the drugs. Unfortunately, knowledge 
about the latter is still very restricted for European eel and certainly requires further 
investigation so as to meet the chemotherapy needs of the eel culture industry and to 
ensure the safety of eel for human consumption. 
Flumequine, one of the few drugs investigated in this respect, appeared to exhibit 
a number of beneficial qualities regarding the efficacy to be expected. The drug is 
rapidly absorbed from the intestinal tract, shows good tissue distribution and remains 
above the minimum inhibitory concentration of most important eel pathogenic bacteria 
for quite a long time (chapters 2, 3). This, in combination with a beneficial influence 
on the natural resistance (chapters 5, 6), may explain many effective treatments and 
hence the repeated selection of this drug. Conversely, the long persistence in eel plasma 
and tissues, as well as the fact that the drug is probably almost exclusively excreted in 
unchanged form (Boon et al, 1991), constitute some major disadvantages of flumequine 
from the viewpoint of public health and environmental protection. Virtually 
impracticable withdrawal periods of about 5 to 6 months (according to data from Boon 
et al. (1991) and chapter 2, respectively), which are needed to safeguard the consumer 
against (detectable) residues, make the drug unfit for application in the final phases of 
eel culture. 
Considering that flumequine proved to augment the eels' defence system (chapter 
5) and their resistance against disease (chapter 6), the drug does seem suitable to treat 
bacterial diseases in early culture phases, at least in as far as there is no risk for residues 
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in consumable eels. However, if the drug is not adequately removed from the holding 
water after treatment, difficulties are still to be expected since residual antibacterial 
drugs, and especially the highly stable quinolones, can persist for a long time in 
recirculation systems (Lunestad, 1992; Schlotfeldt et al, 1995). This may lead to 
repeated uptake of the drug, resistance among bacterial pathogens, and damage to the 
nitrifying bacteria in the bio-filter. Therefore, and also in order to keep up with 
tightening regulations on draining of contaminated effluent, precautionary measures, in 
the form of specially designed filters for drug removal (Marking et al, 1990; Smith et 
al, 1994), may be required. 
Some other major drugs applied to control bacterial diseases in European eels are 
Oxytetracycline and furazolidone. However, on the basis of the presently available 
knowledge, these drugs do not seem to be really suited for this purpose. 
Pharmacokinetic data of Oxytetracycline in eels, originating from a residue study by 
Nouws et al (1993), reveal that the drug is poorly eliminated (t1/4ß in plasma of 215 h 
after intramuscular injection of 60 mg-kg"1 body weight at 22°C) and accumulates in 
bone tissue. Furthermore, suppression of the defence system, as repeatedly demonstrated 
for Oxytetracycline (Grondel and van Muiswinkel, 1986; Descotes, 1988; chapter 6), 
should definitely be avoided in a situation of decreased resistance, which is supposed 
to be the root of bacterial disease in European eels kept under intensive conditions. 
Objections concerning the use of furazolidone, are not so much directed towards the 
mother compound, which appeared to be rather rapidly cleared from the blood of 
European eels (tl/iß=5.5 h after peroral administration of 50 mg-kg"1 body weight at 
23°C; Van der Heijden et al, 1994b), but relate to a persistent protein bound metabolite 
with carcinogenic potential (Nakabeppu and Tatsumi, 1984; Vroomen et al, 1986; 
Vroomen et al, 1988). So, the possible hazards due to the use of this drug far outweigh 
any advantage. Accordingly, the interest in furazolidone and other nitrofuran derivatives 
for aquaculture use decreased and their use in food animals has now largely been 
abandoned in many countries, including The Netherlands. Application of these 
questionable drugs in eel culture, after all, may finally harm the public opinion about 
the production methods and the fish produced. 
Despite the fact that intensive eel culture in north-western Europe exists for over 20 
years, knowledge with regard to antibacterial treatment methods have significantly 
lagged behind the developments in this sector and might be considered as inadequate. 
Therefore, research to support the registration of antibacterial drugs is urgently needed 
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so as to gain legal disposal of a panel of appropriate drugs in the end. At present, over 
20 different antibacterial drugs are approved by the Japanese government for use in their 
indigenous eel species (Okamoto, 1992). Unfortunately, any reports which actually 
verify the suitability of these drugs are either absent or not accessible. Nevertheless, 
some of these drugs might appear to be useful in the European situation as similarities 
in drug behaviour and toxicity between the two species are expected on account of their 
close anatomical and physiological resemblance. 
Final considerations 
In general, there is a worldwide lack of drugs, especially antibacterial drugs, for 
aquaculture use (Schnick, 1992). In most aquatic farming countries, relatively few (and 
sometimes even no) drugs are registered to combat bacterial diseases in food fish, 
despite the fact that these diseases constitute the largest single cause of economic losses 
in aquaculture (Meyer, 1991). The shortage will be mainly due to the large variety in 
existing regulations applied to aquaculture drugs from one country to another and to the 
generally high costs for the pharmaceutical industry to satisfy national registration 
requirements as against a comparatively small market. To overcome the actual impasse 
actions are needed to attract the indispensable interest of the pharmaceutical industry for 
the aquaculture sector, without having to make concessions towards the efficacy or 
safety of drugs. Uniformity in the range of permissible treatments, regulations on residue 
limits and necessary chemical-analytical methods among different countries could 
enlarge the markets for aquaculture drugs, which may result in an extended scope for 
tailoring these drugs to a specific application. At the same time the comparatively 
important trade in aquaculture animals and products could benefit by the arising 
possibilities to facilitate im- and export procedures. Therefore, and in view of the nature 
and extent of the problem, steps towards harmonisation of regulations by far-reaching 
cooperation of agencies concerned, on the level of the European Union (EU), or 
preferably even on a more comprehensive international scale, seems to be the most 
suitable approach. A process which should finally lead to central registration of drugs 
in the EU is currently developing, however, without concrete results for the aquaculture 
sector as yet. 
All veterinary drugs, which are put forward for registration, are evaluated for quality 
and for their efficacy to control the target pathogens, but also for safety with regard to 
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the consumer, the environment and the animals for which they are intended, before 
official approval by the authorities. The impact of a drug on the target animal's health 
is usually examined by routine toxicological studies, but data with regard to possible 
modulating effects on the defence system are not necessarily required. This is 
regrettable, because on the one hand, the use of immunosuppressing drugs, which impair 
the natural resistance of an animal, may eventually end in a vicious circle of infectious 
disease and drug (ab)use. On the other hand, the combined action of a non-compromised 
defence system and an immunostimulating drug will increase the defensive potential and 
consequently support a rapid recovery of the diseased fish. Therefore, it is strongly 
recommended that antibacterial drugs are systematically examined for possible 
unintentional immunological effects and that these data are taken into account during 
future registration procedures. 
Unfortunately, at present there is still no question of a structural approach 
concerning the research on immunomodulating effects of drugs. Results are usually 
difficult to compare as a consequence of differences in several test variables and/or a 
lack of standardization within test protocols. Notwithstanding the risk that 
standardization discourages creativity and restrains the development of new test 
approaches, a certain degree of standardization is certainly needed especially if the tests 
are to be used as regulatory tools. 
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Impact of antibacterial drugs on the health of European eel 
The introduction of intensive culture techniques in fish farming, was accompanied 
by an increased prevalence of infectious diseases as a result of a combination of a high 
infection pressure and decreased resistance of the animals. To reduce losses due to 
bacterial infections, fish are treated with antibacterial drugs. These drugs are generally 
of remarkable value for the control of bacterial infections. However, especially in case 
of excessive use, they may have a number of adverse effects. In this respect there is a 
growing concern about development of resistant bacteria, drug residues in food fish and 
environmental pollution, but also about a possible negative influence on the target 
animals' health (chapter 1). 
During the last decades, several studies have shown that certain antibacterial drugs, 
including some drugs commonly applied in fish culture, exhibit side effects in the form 
of inhibition or stimulation of the immune system. Any antibacterial drug-induced 
immunosuppression, however, is greatly undesirable, because an optimal immune 
function is important for both the final elimination of the pathogen that gave rise to the 
therapy and the resistance against a possible new infection. Stimulation of the defence 
system, on the other hand, may be regarded as a beneficial effect, which fully fits within 
the purpose of an antibacterial treatment. 
Positive as well as negative effects of drugs depend partly on the concentrations of 
the substance in the host following administration. Accordingly, in chapter 2 a 
pharmacokinetic study is described, using flumequine, a second generation quinolone 
derivative which is commonly used in intensive aquaculture, in three important 
cultivated fish species in The Netherlands, namely common carp (Cyprinus carpio L., 
1758), African catfish {Clarias gariepinus Burchell, 1822) and European eel (Anguilla 
anguilla L., 1758). The plasma disposition of the drug was compared between the 
respective species after a single peroral administration at a customary dose of 18 mg-kg" 
1
 body weight. All species showed rapid absorption followed by biphasic plasma 
depletion. Apart from that, significant interspecies differences were observed for most 
of the determined pharmacokinetic parameters. Mean highest plasma flumequine 
concentrations were, in decreasing order, 6136 ngml"1 in carp, 4074 ngml"1 in eel and 
1179 ng-ml"1 in catfish. Moreover, calculation of the mean distribution and elimination 
133 
Summary 
half-lives revealed 3.4 and 104.3 h for carp, 7.3 and 59.5 h for catfish and 56.7 and 
451.2 h for eel. So, to achieve equivalent drug efficacy and to minimize the probability 
of residues as a result of medication, dosage regimes and withdrawal periods should be 
adapted for each species. 
Most striking was the extremely slow elimination of flumequine in plasma of eels. 
Hence, in chapter 3 the tissue distribution and residue elimination of the drug was 
studied in more detail in this species after a single intramuscular injection. 
Concentrations of flumequine in muscle and liver were respectively similar and higher 
than in plasma during the investigated period (44 days). Elimination of the drug from 
the examined tissues was very slow and in the same order of magnitude as from the 
plasma. After an observation period of more than 6 weeks the mean drug concentration 
in plasma and different tissues was still above 85 ng-ml"1 or -g"1, which is higher than 
the minimum inhibitory concentration (MIC) reported for most important eel pathogenic 
bacteria. This may (partly) explain the use of flumequine in eel culture, but also 
emphasizes the aforementioned risk for residues of this drug in eels destined for 
consumption. In addition, the long drug persistence in plasma and tissues makes eel a 
suitable model to study a possible influence of flumequine on the natural resistance and 
the associated health condition. 
Lack of appropriate test assays for in vivo or ex vivo determination of suitable 
immunological parameters necessitated preliminary development of some tools. To this 
end, monoclonal antibodies (mAbs) to European eel immunoglobulin (Ig) were 
produced, characterized and tested for applicability in a number of 
immuno(cyto)chemical assays (chapter 4). The selected mAbs, WEI 1 and WEI 2, were 
specifically reactive with Ig heavy and light polypeptide chain, respectively. WEI 1 was 
reactive with all or nearly all Ig molecules, B cells and plasma cells, whereas WEI 2 
reacted with a subpopulation of those cells. Therefore, the former mAb was the most 
suitable reagent for flow cytometric determination of Ig-bearing (B) lymphocyte 
proportions. However, both mAbs appeared to be equally useful for detection of antigen-
specific antibodies in plasma by means of an enzyme-linked immunosorbent assay 
(ELISA). 
In chapter 5 the influence of flumequine on the proliferative capacity of lymphoid 
cells in eels was studied. For this purpose a newly developed in vivo test was applied. 
Essentially, this test included peroral drug administration followed by successive 
intraperitoneal injections with a mitogen, being either concanavalin A (Con A) or 
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lipopolysaccharide (LPS), and the immunocytochemically demonstrable thymidine 
analogue 5-bromo-2'-deoxyuridine. Subsequent counting of proliferated cells in 
peripheral blood smears revealed that flumequine itself possesses mitogenic properties. 
Moreover, the drug appeared to enhance the proliferative response of lymphoid cells to 
LPS, whereas the Con A response was not significantly affected after flumequine 
treatment. Flow cytometric analysis of peripheral blood lymphoid cells showed a 
significant reduction of the proportion of surface immunoglobulin positive cells in the 
flumequine-treated animals. It was concluded that flumequine enhances proliferation of 
lymphoid cells (probably surface immunoglobulin negative cells) in eels. 
The influence of flumequine on a basic immunological mechanism, as described 
above, does not allow a sound judgement of the functioning of the entire defence system 
with regard to resistance to infections. Therefore, in chapter 6 the effect of flumequine 
and also Oxytetracycline, an antibacterial drug with known immunosuppressive 
properties, was finally investigated by means of a challenge test. The eels were 
experimentally infected with Anguillicola crassus (Kuwahara, Niimi et Itagaki, 1974), 
a commonly occurring eel parasitic nematode residing in the swimbladder. Eight weeks 
after oral administration of infective larvae, the mean recovery of the parasites in 
flumequine-treated eels was lower than in the non-medicated control animals and 
significantly lower than in oxytetracycline-treated eels. Mean numbers of peripheral 
blood granulocytes and B-lymphocytes as well as the total amount of circulating 
lymphoid cells showed an increase as a result of the infection, while drug treatment 
significantly affected the quantities of the lymphoid cells. The difference in protection 
against the parasite after flumequine or Oxytetracycline administration, pointed to a 
modulation of the fish resistance as a result of the drug treatments. The fact that specific 
antibodies to the parasite were not found favoured an effect on the cellular rather than 
on the humoral response, which is in accordance with previous suggestions. 
The immunostimulating effect and the pharmacokinetic characteristics of flumequine 
which appeared from the present study, in combination with the MIC values reported 
for a number of important pathogens, indicate that flumequine can be an effective drug 
to control bacterial infections in eel. However, the slow elimination and the long 
withdrawal times which are consequently needed, make the drug unsuitable for routine 
application in eel culture (chapter 7). 
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Invloed van antibacteriële medicijnen op de gezondheid van Europese aal 
De invoering van intensieve houderijmethoden in de visteelt, ging gepaard met een 
verhoogde prevalentie van infectieziekten ten gevolge van een combinatie van een hoge 
infectiedruk en een verminderde weerstand van de dieren. Om verliezen ten gevolge van 
bacteriële infecties te beperken worden antibacteriële medicijnen aan de vissen 
toegediend. Het is algemeen bekend dat deze middelen buitengewoon belangrijk zijn 
voor de beheersing van genoemde infecties. Vooral bij overdadig gebruik kunnen deze 
echter een aantal nadelige effecten hebben. In dit verband is er een toenemende 
bezorgdheid over het ontstaan van resistente bacteriën, geneesmiddelresiduen in 
consumptievis en de verontreiniging van het milieu, maar ook over een mogelijk 
negatieve invloed op de gezondheid van de behandelde vissen (hoofdstuk 1). 
Gedurende de afgelopen decennia werd meerdere malen aangetoond dat bepaalde, 
ook in de visteelt algemeen toegepaste, antibacteriële geneesmiddelen bijwerkingen 
vertonen in de vorm van remming of stimulatie van het immuunsysteem. Iedere 
immunosuppressie als gevolg van antibacteriële medicatie is echter hoogst ongewenst, 
omdat een efficiënte werking van het afweersysteem zowel van belang is voor de 
uiteindelijke eliminatie van het pathogeen waarvoor de therapie werd ingesteld, als voor 
de weerstand tegen een eventuele nieuwe infectie. Stimulatie van de afweer kan 
daarentegen worden beschouwd als een gunstig effect, dat volkomen past bij het doel 
van een antibacteriële therapie. 
Zowel positieve als negatieve effecten van geneesmiddelen zullen gedeeltelijk 
afhankelijk zijn van het concentratieverloop van het middel in het dier. 
Dienovereenkomstig werd in hoofdstuk 2 begonnen met een farmacokinetisch 
experiment met gebruikmaking van flumequine, een tweede generatie quinolone derivaat 
dat algemeen wordt toegepast in de intensieve aquacultuur, en drie voor de Nederlandse 
situatie belangrijke vissoorten, te weten gewone karper {Cyprinus carpio L., 1758), 
Afrikaanse meerval (Clarias gariepinus Burchell, 1822) en Europese aal (Anguilla 
anguilla L.,1758). De afname van de concentratie van het geneesmiddel in plasma werd 
vergeleken bij de respectieve soorten na eenmalige perorale toediening van een 
gebruikelijke dosis van 18 mg-kg"1 lichaamsgewicht. Alle drie de soorten vertoonden 
een snelle absorptie gevolg door een bifasische afname van de concentratie in het 
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plasma. Verder werden er significante verschillen waargenomen tussen de soorten met 
betrekking tot het merendeel van de bepaalde farmacokinetische parameters. De hoogste 
gemiddelde flumequine-spiegels in plasma waren, in afnemende volgorde, 6136 ng-ml"1 
in karper, 4074 ng-ml"1 in aal en 1179 ng-ml"1 in meerval. Berekening van de 
gemiddelde distributie- en eliminatie-halfwaardetijden leverde voorts 3.4 en 104.3 h voor 
de karper, 7.3 en 59.5 h voor de meerval en 56.7 en 451.2 h voor de aal. Dit betekent 
dat voor een gelijkwaardige werkzaamheid en ter voorkoming van residuen in 
consumptievis, dosering en wachttijd dienen te worden aan gepast per soort. 
Zeer opvallend was de uitermate trage eliminatie van flumequine in plasma van de 
aal. Derhalve werd in hoofdstuk 3 uitvoeriger gekeken naar de verdeling over de 
verschillende weefsels en de eliminatie van residuen van het middel in deze vissoort na 
een eenmalige intramusculaire injectie. De concentraties van flumequine in spier en 
lever waren respectievelijk overeenkomstig en hoger dan de in plasma gemeten 
concentraties gedurende de bestudeerde periode (44 dagen). De eliminatie van het 
middel uit de onderzochte weefsels was zeer langzaam en lag in dezelfde orde van 
grootte als de eliminatie uit plasma. Na ruim 6 weken was de flumequine-concentratie 
in plasma en de verschillende weefsels nog steeds hoger dan 85 ng-ml"1 of g'1, hetgeen 
hoog genoeg is voor remming van de meest belangrijke, voor aal pathogène bacteriën. 
Dit zou (deels) het gebruik van flumequine in de aalmesterij kunnen verklaren, maar 
benadrukt tevens het eerder genoemde gevaar voor residuen van dit geneesmiddel in 
voor de consumptie bestemde aal. De lange verblijfsduur van het farmacon in plasma 
en de verschillende weefsels maakt aal bovendien tot een geschikt model voor de 
bestudering van een eventuele invloed van flumequine op de natuurlijke weerstand en 
de hieraan gerelateerde gezondheidsstatus van de vis. 
Gebrek aan passende testen voor in vivo of ex vivo bepaling van geschikte 
immunologische parameters maakte echter een voorafgaande ontwikkeling van het 
benodigde 'gereedschap' noodzakelijk. Hiertoe werden monoklonale antilichamen 
(mAbs) tegen Immunoglobuline (Ig) van de Europese aal gemaakt. Vervolgens werd het 
reactiepatroon van de mAbs gekarakteriseerd en werd hun toepasbaarheid in een aantal 
immuno(cyto)chemische testen nagegaan (Hoofdstuk 4). De geselecteerde mAbs, WEI 
1 en WEI 2, vertoonden een specifieke reactie met respectievelijk de zware en lichte 
polypeptideketen van het Ig. WEI 1 reageerde met alle of nagenoeg alle Ig-moleculen, 
B cellen en plasma cellen, terwijl WEI 2 met een subpopulatie van deze cellen 
reageerde. WEI 1 was daarom het meest geschikt voor flow-cytometrische bepaling van 
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het percentage Ig-dragende (B) lymfocyten. Beide mAbs bleken echter in gelijke mate 
geschikt te zijn voor de detectie van antigeen-specifieke antilichamen in plasma met 
behulp van een 'enzyme-linked immunosorbent assay' (ELISA). 
In hoofdstuk 5 werd onderzocht in hoeverre flumequine invloed heeft op het 
proliferatievermogen van lymfoïde cellen in aal. Hiervoor werd gebruik gemaakt van een 
nieuwe in vivo test. Deze test behelsde in wezen perorale toediening van het 
geneesmiddel, gevolgd door intraperitoneale injecties van achtereenvolgens een 
mitogeen, hetzij concanavaline A (Con A) of lipopolysaccharide (LPS), en het 
immunocytochemisch aantoonbare thymidine analoog 5-bromo-2'-deoxyuridine. Door 
vervolgens het aantal geprolifereerde cellen in bloeduitstrijkjes te tellen bleek dat 
flumequine op zich mitogene eigenschappen bezit. Verder bleek het geneesmiddel een 
verhoogde respons op LPS te bewerkstelligen, terwijl geen significant effect gevonden 
werd op de proliferatie ten gevolge van Con A. Flow-cytometrische analyse van 
lymfoïde cellen in perifeer bloed toonde aan dat het relatieve aantal lymfocyten met 
membraangebonden Ig significant verlaagd was in de met flumequine behandelde dieren. 
Er werd zodoende geconcludeerd dat flumequine de proliferatie van lymfoïde cellen 
(waarschijnlijk degenen zonder membraangebonden Ig) in aal bevordert. 
De invloed van flumequine op een elementair immunologisch proces, zoals 
hierboven beschreven werd, geeft echter geen volledig inzicht in het functioneren van 
het afweersysteem als geheel met betrekking tot de weerstand tegen infecties. In 
hoofdstuk 6 werd daarom tenslotte het effect van flumequine alsmede Oxytetracycline, 
een antibioticum met immunosuppressieve eigenschappen, onderzocht met behulp van 
een 'challenge experiment'. Aal werd hiervoor oraal geïnfecteerd met Anguillicola 
crassus (Kuwahara, Niimi et Itagaki, 1974), een algemeen voorkomende parasitaire 
nematode van de zwemblaas in aal. Acht weken na toediening van de infectieuze larven 
was het gemiddelde, in de zwemblaas aangetroffen aantal parasieten in aal behandeld 
met flumequine lager dan in de niet-gemedicineerde controlevissen en significant lager 
dan in de met Oxytetracycline behandelde aal. De gemiddelde aantallen granulocyten en 
B-lymfocyten in perifeer bloed, evenals het totale aantal circulerende lymfoïde cellen, 
waren verhoogd als gevolg van de infectie, terwijl de geneesmiddelbehandeling een 
significant effect bleek te hebben op de hoeveelheden lymfoïde cellen. Het verschil in 
bescherming tegen de parasiet na toediening van flumequine dan wel Oxytetracycline 
wees op een modulatie van de weerstand ten gevolge van deze behandelingen. Het feit 
dat geen specifieke antilichamen tegen de parasiet werden gevonden, gaf aan dat het 
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waargenomen effect eerder moet worden toegeschreven aan een invloed op de cellulaire 
dan op de humorale respons, hetgeen overeenstemt met suggesties hieromtrent in het 
voorgaande hoofdstuk. 
Het immunostimulerende effect en de farmacokinetische karakteristieken van 
flumequine die uit het onderhavige onderzoek naar voren kwamen, in combinatie met 
de in de literatuur vermelde gegevens met betrekking tot de gevoeligheid van een aantal 
belangrijke pathogenen voor flumequine, geven aan dat het een effectief middel kan zijn 
tegen bacteriè'le infecties in aal. Gezien de trage eliminatie en de hierdoor vereiste lange 
wachttijden is het middel echter niet geschikt voor routinematig gebruik in de 
aalmesterij (hoofdstuk 7). 
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